Antigens: Substances that are recognized by the immune system and induce an immune reaction.Antigens, Bacterial: Substances elaborated by bacteria that have antigenic activity.Antigens, Neoplasm: Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.Antigens, Surface: Antigens on surfaces of cells, including infectious or foreign cells or viruses. They are usually protein-containing groups on cell membranes or walls and may be isolated.Antigens, Viral: Substances elaborated by viruses that have antigenic activity.Antigens, Protozoan: Any part or derivative of any protozoan that elicits immunity; malaria (Plasmodium) and trypanosome antigens are presently the most frequently encountered.Antigens, Polyomavirus Transforming: Polyomavirus antigens which cause infection and cellular transformation. The large T antigen is necessary for the initiation of viral DNA synthesis, repression of transcription of the early region and is responsible in conjunction with the middle T antigen for the transformation of primary cells. Small T antigen is necessary for the completion of the productive infection cycle.HLA Antigens: Antigens determined by leukocyte loci found on chromosome 6, the major histocompatibility loci in humans. They are polypeptides or glycoproteins found on most nucleated cells and platelets, determine tissue types for transplantation, and are associated with certain diseases.Pancreatic Neoplasms: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.Antigens, Fungal: Substances of fungal origin that have antigenic activity.Antigens, CD: Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.Antigens, Helminth: Any part or derivative of a helminth that elicits an immune reaction. The most commonly seen helminth antigens are those of the schistosomes.H-2 Antigens: The major group of transplantation antigens in the mouse.Carcinoembryonic Antigen: A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment.Antigens, Viral, Tumor: Those proteins recognized by antibodies from serum of animals bearing tumors induced by viruses; these proteins are presumably coded for by the nucleic acids of the same viruses that caused the neoplastic transformation.Neoplasms, Cystic, Mucinous, and Serous: Neoplasms containing cyst-like formations or producing mucin or serum.Antibodies, Monoclonal: Antibodies produced by a single clone of cells.Receptors, Antigen, T-Cell: Molecules on the surface of T-lymphocytes that recognize and combine with antigens. The receptors are non-covalently associated with a complex of several polypeptides collectively called CD3 antigens (ANTIGENS, CD3). Recognition of foreign antigen and the major histocompatibility complex is accomplished by a single heterodimeric antigen-receptor structure, composed of either alpha-beta (RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA) or gamma-delta (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA) chains.HLA-DR Antigens: A subclass of HLA-D antigens that consist of alpha and beta chains. The inheritance of HLA-DR antigens differs from that of the HLA-DQ ANTIGENS and HLA-DP ANTIGENS.Proliferating Cell Nuclear Antigen: Nuclear antigen with a role in DNA synthesis, DNA repair, and cell cycle progression. PCNA is required for the coordinated synthesis of both leading and lagging strands at the replication fork during DNA replication. PCNA expression correlates with the proliferation activity of several malignant and non-malignant cell types.Histocompatibility Antigens: A group of antigens that includes both the major and minor histocompatibility antigens. The former are genetically determined by the major histocompatibility complex. They determine tissue type for transplantation and cause allograft rejections. The latter are systems of allelic alloantigens that can cause weak transplant rejection.Skin Neoplasms: Tumors or cancer of the SKIN.Receptors, Antigen, B-Cell: IMMUNOGLOBULINS on the surface of B-LYMPHOCYTES. Their MESSENGER RNA contains an EXON with a membrane spanning sequence, producing immunoglobulins in the form of type I transmembrane proteins as opposed to secreted immunoglobulins (ANTIBODIES) which do not contain the membrane spanning segment.Histocompatibility Antigens Class II: Large, transmembrane, non-covalently linked glycoproteins (alpha and beta). Both chains can be polymorphic although there is more structural variation in the beta chains. The class II antigens in humans are called HLA-D ANTIGENS and are coded by a gene on chromosome 6. In mice, two genes named IA and IE on chromosome 17 code for the H-2 antigens. The antigens are found on B-lymphocytes, macrophages, epidermal cells, and sperm and are thought to mediate the competence of and cellular cooperation in the immune response. The term IA antigens used to refer only to the proteins encoded by the IA genes in the mouse, but is now used as a generic term for any class II histocompatibility antigen.Epitopes: Sites on an antigen that interact with specific antibodies.Prostate-Specific Antigen: A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.O Antigens: The lipopolysaccharide-protein somatic antigens, usually from gram-negative bacteria, important in the serological classification of enteric bacilli. The O-specific chains determine the specificity of the O antigens of a given serotype. O antigens are the immunodominant part of the lipopolysaccharide molecule in the intact bacterial cell. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed)Antigens, Tumor-Associated, Carbohydrate: Carbohydrate antigens expressed by malignant tissue. They are useful as tumor markers and are measured in the serum by means of a radioimmunoassay employing monoclonal antibodies.T-Lymphocytes: Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.Antigens, CD15: A trisaccharide antigen expressed on glycolipids and many cell-surface glycoproteins. In the blood the antigen is found on the surface of NEUTROPHILS; EOSINOPHILS; and MONOCYTES. In addition, CD15 antigen is a stage-specific embryonic antigen.Neoplasms, Multiple Primary: Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.Antigens, CD8: Differentiation antigens found on thymocytes and on cytotoxic and suppressor T-lymphocytes. CD8 antigens are members of the immunoglobulin supergene family and are associative recognition elements in MHC (Major Histocompatibility Complex) Class I-restricted interactions.HLA-A2 Antigen: A specific HLA-A surface antigen subtype. Members of this subtype contain alpha chains that are encoded by the HLA-A*02 allele family.Immunohistochemistry: Histochemical localization of immunoreactive substances using labeled antibodies as reagents.Enzyme-Linked Immunosorbent Assay: An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.Kidney Neoplasms: Tumors or cancers of the KIDNEY.Antigens, CD3: Complex of at least five membrane-bound polypeptides in mature T-lymphocytes that are non-covalently associated with one another and with the T-cell receptor (RECEPTORS, ANTIGEN, T-CELL). The CD3 complex includes the gamma, delta, epsilon, zeta, and eta chains (subunits). When antigen binds to the T-cell receptor, the CD3 complex transduces the activating signals to the cytoplasm of the T-cell. The CD3 gamma and delta chains (subunits) are separate from and not related to the gamma/delta chains of the T-cell receptor (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA).Immunoglobulin G: The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.Blood Group Antigens: Sets of cell surface antigens located on BLOOD CELLS. They are usually membrane GLYCOPROTEINS or GLYCOLIPIDS that are antigenically distinguished by their carbohydrate moieties.Hepatitis B Surface Antigens: Those hepatitis B antigens found on the surface of the Dane particle and on the 20 nm spherical and tubular particles. Several subspecificities of the surface antigen are known. These were formerly called the Australia antigen.Cross Reactions: Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen.Mice, Inbred BALB CNeoplasms, Second Primary: Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.HLA-A Antigens: Polymorphic class I human histocompatibility (HLA) surface antigens present on almost all nucleated cells. At least 20 antigens have been identified which are encoded by the A locus of multiple alleles on chromosome 6. They serve as targets for T-cell cytolytic responses and are involved with acceptance or rejection of tissue/organ grafts.Molecular Sequence Data: Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.Histocompatibility Antigens Class I: Membrane glycoproteins consisting of an alpha subunit and a BETA 2-MICROGLOBULIN beta subunit. In humans, highly polymorphic genes on CHROMOSOME 6 encode the alpha subunits of class I antigens and play an important role in determining the serological specificity of the surface antigen. Class I antigens are found on most nucleated cells and are generally detected by their reactivity with alloantisera. These antigens are recognized during GRAFT REJECTION and restrict cell-mediated lysis of virus-infected cells.Adenocarcinoma, Mucinous: An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)Lung Neoplasms: Tumors or cancer of the LUNG.Antibody Specificity: The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site.Lymphocyte Activation: Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION.Antigens, CD45: High-molecular weight glycoproteins uniquely expressed on the surface of LEUKOCYTES and their hemopoietic progenitors. They contain a cytoplasmic protein tyrosine phosphatase activity which plays a role in intracellular signaling from the CELL SURFACE RECEPTORS. The CD45 antigens occur as multiple isoforms that result from alternative mRNA splicing and differential usage of three exons.Thyroid Neoplasms: Tumors or cancer of the THYROID GLAND.Immunoenzyme Techniques: Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.Neoplasms, Experimental: Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.HLA-D Antigens: Human immune-response or Class II antigens found mainly, but not exclusively, on B-lymphocytes and produced from genes of the HLA-D locus. They are extremely polymorphic families of glycopeptides, each consisting of two chains, alpha and beta. This group of antigens includes the -DR, -DQ and -DP designations, of which HLA-DR is most studied; some of these glycoproteins are associated with certain diseases, possibly of immune etiology.Antigens, CD4: 55-kDa antigens found on HELPER-INDUCER T-LYMPHOCYTES and on a variety of other immune cell types. CD4 antigens are members of the immunoglobulin supergene family and are implicated as associative recognition elements in MAJOR HISTOCOMPATIBILITY COMPLEX class II-restricted immune responses. On T-lymphocytes they define the helper/inducer subset. CD4 antigens also serve as INTERLEUKIN-15 receptors and bind to the HIV receptors, binding directly to the HIV ENVELOPE PROTEIN GP120.Neoplasm Proteins: Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.Liver Neoplasms: Tumors or cancer of the LIVER.Receptors, Antigen: Molecules on the surface of B- and T-lymphocytes that recognize and combine with specific antigens.Fluorescent Antibody Technique: Test for tissue antigen using either a direct method, by conjugation of antibody with fluorescent dye (FLUORESCENT ANTIBODY TECHNIQUE, DIRECT) or an indirect method, by formation of antigen-antibody complex which is then labeled with fluorescein-conjugated anti-immunoglobulin antibody (FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT). The tissue is then examined by fluorescence microscopy.Hepatitis B Antigens: Antigens of the virion of the HEPATITIS B VIRUS or the Dane particle, its surface (HEPATITIS B SURFACE ANTIGENS), core (HEPATITIS B CORE ANTIGENS), and other associated antigens, including the HEPATITIS B E ANTIGENS.Myeloproliferative Disorders: Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.DNA, Neoplasm: DNA present in neoplastic tissue.Antigen-Antibody Reactions: The processes triggered by interactions of ANTIBODIES with their ANTIGENS.B-Lymphocytes: Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.Antigens, CD1: Glycoproteins expressed on cortical thymocytes and on some dendritic cells and B-cells. Their structure is similar to that of MHC Class I and their function has been postulated as similar also. CD1 antigens are highly specific markers for human LANGERHANS CELLS.Cell Line: Established cell cultures that have the potential to propagate indefinitely.Antibody Formation: The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS.Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.Antibodies, Bacterial: Immunoglobulins produced in a response to BACTERIAL ANTIGENS.Immune Sera: Serum that contains antibodies. It is obtained from an animal that has been immunized either by ANTIGEN injection or infection with microorganisms containing the antigen.Antigens, Differentiation: Antigens expressed primarily on the membranes of living cells during sequential stages of maturation and differentiation. As immunologic markers they have high organ and tissue specificity and are useful as probes in studies of normal cell development as well as neoplastic transformation.Cystadenoma: A benign neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. In some instances, considerable portions of the neoplasm, or even the entire mass, may be cystic. (Stedman, 25th ed)Lymphoma: A general term for various neoplastic diseases of the lymphoid tissue.MART-1 Antigen: A melanosome-specific protein that plays a role in the expression, stability, trafficking, and processing of GP100 MELANOMA ANTIGEN, which is critical to the formation of Stage II MELANOSOMES. The protein is used as an antigen marker for MELANOMA cells.HLA-B Antigens: Class I human histocompatibility (HLA) surface antigens encoded by more than 30 detectable alleles on locus B of the HLA complex, the most polymorphic of all the HLA specificities. Several of these antigens (e.g., HLA-B27, -B7, -B8) are strongly associated with predisposition to rheumatoid and other autoimmune disorders. Like other class I HLA determinants, they are involved in the cellular immune reactivity of cytolytic T lymphocytes.Amino Acid Sequence: The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.Immunization: Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow).Parotid Neoplasms: Tumors or cancer of the PAROTID GLAND.Tumor Markers, Biological: Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.Neoplasms, Connective and Soft Tissue: Neoplasms developing from some structure of the connective and subcutaneous tissue. The concept does not refer to neoplasms located in connective or soft tissue.Neoplasms, Plasma Cell: Neoplasms associated with a proliferation of a single clone of PLASMA CELLS and characterized by the secretion of PARAPROTEINS.Appendiceal Neoplasms: Tumors or cancer of the APPENDIX.Gastrointestinal Neoplasms: Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL.Cystadenoma, Mucinous: A multilocular tumor with mucin secreting epithelium. They are most often found in the ovary, but are also found in the pancreas, appendix, and rarely, retroperitoneal and in the urinary bladder. They are considered to have low-grade malignant potential.Colonic Neoplasms: Tumors or cancer of the COLON.Endocrine Gland Neoplasms: Tumors or cancer of the ENDOCRINE GLANDS.HIV Antigens: Antigens associated with specific proteins of the human adult T-cell immunodeficiency virus (HIV); also called HTLV-III-associated and lymphadenopathy-associated virus (LAV) antigens.Antigens, CD80: A costimulatory ligand expressed by ANTIGEN-PRESENTING CELLS that binds to CTLA-4 ANTIGEN with high specificity and to CD28 ANTIGEN with low specificity. The interaction of CD80 with CD28 ANTIGEN provides a costimulatory signal to T-LYMPHOCYTES, while its interaction with CTLA-4 ANTIGEN may play a role in inducing PERIPHERAL TOLERANCE.Eye Neoplasms: Tumors or cancer of the EYE.Mice, Inbred C57BLSpleen: An encapsulated lymphatic organ through which venous blood filters.Epstein-Barr Virus Nuclear Antigens: Nuclear antigens encoded by VIRAL GENES found in HUMAN HERPESVIRUS 4. At least six nuclear antigens have been identified.Carcinoma, Pancreatic Ductal: Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.Antigens, CD19: Differentiation antigens expressed on B-lymphocytes and B-cell precursors. They are involved in regulation of B-cell proliferation.Neoplasm Staging: Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.Base Sequence: The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.Flow Cytometry: Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.Neoplasms, Vascular Tissue: Neoplasms composed of vascular tissue. This concept does not refer to neoplasms located in blood vessels.Nose Neoplasms: Tumors or cancer of the NOSE.Testicular Neoplasms: Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.Neoplasms, Radiation-Induced: Tumors, cancer or other neoplasms produced by exposure to ionizing or non-ionizing radiation.Dog Diseases: Diseases of the domestic dog (Canis familiaris). This term does not include diseases of wild dogs, WOLVES; FOXES; and other Canidae for which the heading CARNIVORA is used.Ki-67 Antigen: A CELL CYCLE and tumor growth marker which can be readily detected using IMMUNOCYTOCHEMISTRY methods. Ki-67 is a nuclear antigen present only in the nuclei of cycling cells.Salivary Gland Neoplasms: Tumors or cancer of the SALIVARY GLANDS.Antibodies: Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).Adenoma: A benign epithelial tumor with a glandular organization.Adenocarcinoma, Papillary: An adenocarcinoma containing finger-like processes of vascular connective tissue covered by neoplastic epithelium, projecting into cysts or the cavity of glands or follicles. It occurs most frequently in the ovary and thyroid gland. (Stedman, 25th ed)Carcinoma, Papillary: A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)Antigens, Heterophile: Antigens stimulating the formation of, or combining with heterophile antibodies. They are cross-reacting antigens found in phylogenetically unrelated species.Hematologic Neoplasms: Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.Prostatic Neoplasms: Tumors or cancer of the PROSTATE.Sensitivity and Specificity: Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)Mice, Inbred Strains: Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation.Hepatitis B Core Antigens: The hepatitis B antigen within the core of the Dane particle, the infectious hepatitis virion.Immunoglobulin M: A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally being called a macroglobulin.Cystadenocarcinoma: A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed)Neoplasms, Muscle Tissue: Neoplasms composed of muscle tissue: skeletal, cardiac, or smooth. The concept does not refer to neoplasms located in muscles.Uterine Neoplasms: Tumors or cancer of the UTERUS.Antigens, CD40: A member of the tumor necrosis factor receptor superfamily with specificity for CD40 LIGAND. It is found on mature B-LYMPHOCYTES and some EPITHELIAL CELLS, lymphoid DENDRITIC CELLS. Evidence suggests that CD40-dependent activation of B-cells is important for generation of memory B-cells within the germinal centers. Mutations of the gene for CD40 antigen result in HYPER-IGM IMMUNODEFICIENCY SYNDROME, TYPE 3. Signaling of the receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.Cystadenocarcinoma, Mucinous: A malignant cystic or semisolid tumor most often occurring in the ovary. Rarely, one is solid. This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar epithelial cells; in others, the epithelium consists of many layers of cells that have lost normal structure entirely. In the more undifferentiated tumors, one may see sheets and nests of tumor cells that have very little resemblance to the parent structure. (Hughes, Obstetric-Gynecologic Terminology, 1972, p184)Intestinal Neoplasms: Tumors or cancer of the INTESTINES.Immunodiffusion: Technique involving the diffusion of antigen or antibody through a semisolid medium, usually agar or agarose gel, with the result being a precipitin reaction.Autoantigens: Endogenous tissue constituents that have the ability to interact with AUTOANTIBODIES and cause an immune response.Dendritic Cells: Specialized cells of the hematopoietic system that have branch-like extensions. They are found throughout the lymphatic system, and in non-lymphoid tissues such as SKIN and the epithelia of the intestinal, respiratory, and reproductive tracts. They trap and process ANTIGENS, and present them to T-CELLS, thereby stimulating CELL-MEDIATED IMMUNITY. They are different from the non-hematopoietic FOLLICULAR DENDRITIC CELLS, which have a similar morphology and immune system function, but with respect to humoral immunity (ANTIBODY PRODUCTION).Thymus Neoplasms: Tumors or cancer of the THYMUS GLAND.Neoplasms, Glandular and Epithelial: Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue.Cells, Cultured: Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.Soft Tissue Neoplasms: Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.Bone Neoplasms: Tumors or cancer located in bone tissue or specific BONES.Molecular Weight: The sum of the weight of all the atoms in a molecule.Antigens, Thy-1: A group of differentiation surface antigens, among the first to be discovered on thymocytes and T-lymphocytes. Originally identified in the mouse, they are also found in other species including humans, and are expressed on brain neurons and other cells.Adenocarcinoma: A malignant epithelial tumor with a glandular organization.Forssman Antigen: A glycolipid, cross-species antigen that induces production of antisheep hemolysin. It is present on the tissue cells of many species but absent in humans. It is found in many infectious agents.Antigen-Antibody Complex: The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes IMMUNE COMPLEX DISEASES.Simian virus 40: A species of POLYOMAVIRUS originally isolated from Rhesus monkey kidney tissue. It produces malignancy in human and newborn hamster kidney cell cultures.H-Y Antigen: A sex-specific cell surface antigen produced by the sex-determining gene of the Y chromosome in mammals. It causes syngeneic grafts from males to females to be rejected and interacts with somatic elements of the embryologic undifferentiated gonad to produce testicular organogenesis.Antigen-Presenting Cells: A heterogeneous group of immunocompetent cells that mediate the cellular immune response by processing and presenting antigens to the T-cells. Traditional antigen-presenting cells include MACROPHAGES; DENDRITIC CELLS; LANGERHANS CELLS; and B-LYMPHOCYTES. FOLLICULAR DENDRITIC CELLS are not traditional antigen-presenting cells, but because they hold antigen on their cell surface in the form of IMMUNE COMPLEXES for B-cell recognition they are considered so by some authors.Vascular Neoplasms: Neoplasms located in the vasculature system, such as ARTERIES and VEINS. They are differentiated from neoplasms of vascular tissue (NEOPLASMS, VASCULAR TISSUE), such as ANGIOFIBROMA or HEMANGIOMA.Lymphocytes: White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS.Neoplasms, Adnexal and Skin Appendage: Neoplasms composed of sebaceous or sweat gland tissue or tissue of other skin appendages. The concept does not refer to neoplasms located in the sebaceous or sweat glands or in the other skin appendages.CA-19-9 Antigen: Sialylated Lewis blood group carbohydrate antigen found in many adenocarcinomas of the digestive tract, especially pancreatic tumors.T-Lymphocytes, Cytotoxic: Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2.Palatal Neoplasms: Tumors or cancer of the PALATE, including those of the hard palate, soft palate and UVULA.Complement Fixation Tests: Serologic tests based on inactivation of complement by the antigen-antibody complex (stage 1). Binding of free complement can be visualized by addition of a second antigen-antibody system such as red cells and appropriate red cell antibody (hemolysin) requiring complement for its completion (stage 2). Failure of the red cells to lyse indicates that a specific antigen-antibody reaction has taken place in stage 1. If red cells lyse, free complement is present indicating no antigen-antibody reaction occurred in stage 1.HLA-DQ Antigens: A group of the D-related HLA antigens found to differ from the DR antigens in genetic locus and therefore inheritance. These antigens are polymorphic glycoproteins comprising alpha and beta chains and are found on lymphoid and other cells, often associated with certain diseases.Neoplasm Invasiveness: Ability of neoplasms to infiltrate and actively destroy surrounding tissue.Ovalbumin: An albumin obtained from the white of eggs. It is a member of the serpin superfamily.Colorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.Antigens, CD86: A costimulatory ligand expressed by ANTIGEN-PRESENTING CELLS that binds to CD28 ANTIGEN with high specificity and to CTLA-4 ANTIGEN with low specificity. The interaction of CD86 with CD28 ANTIGEN provides a stimulatory signal to T-LYMPHOCYTES, while its interaction with CTLA-4 ANTIGEN may play a role in inducing PERIPHERAL TOLERANCE.Rabbits: The species Oryctolagus cuniculus, in the family Leporidae, order LAGOMORPHA. Rabbits are born in burrows, furless, and with eyes and ears closed. In contrast with HARES, rabbits have 22 chromosome pairs.Antigens, CD79: A component of the B-cell antigen receptor that is involved in B-cell antigen receptor heavy chain transport to the PLASMA MEMBRANE. It is expressed almost exclusively in B-LYMPHOCYTES and serves as a useful marker for B-cell NEOPLASMS.Sweat Gland NeoplasmsImmunity, Cellular: Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role.Time Factors: Elements of limited time intervals, contributing to particular results or situations.Splenic Neoplasms: Tumors or cancer of the SPLEEN.Bile Duct Neoplasms: Tumors or cancer of the BILE DUCTS.Antibodies, Viral: Immunoglobulins produced in response to VIRAL ANTIGENS.Receptors, Antigen, T-Cell, alpha-beta: T-cell receptors composed of CD3-associated alpha and beta polypeptide chains and expressed primarily in CD4+ or CD8+ T-cells. Unlike immunoglobulins, the alpha-beta T-cell receptors recognize antigens only when presented in association with major histocompatibility (MHC) molecules.Neoplasms, Complex and Mixed: Neoplasms composed of more than one type of neoplastic tissue.Clone Cells: A group of genetically identical cells all descended from a single common ancestral cell by mitosis in eukaryotes or by binary fission in prokaryotes. Clone cells also include populations of recombinant DNA molecules all carrying the same inserted sequence. (From King & Stansfield, Dictionary of Genetics, 4th ed)Immunoelectrophoresis: A technique that combines protein electrophoresis and double immunodiffusion. In this procedure proteins are first separated by gel electrophoresis (usually agarose), then made visible by immunodiffusion of specific antibodies. A distinct elliptical precipitin arc results for each protein detectable by the antisera.CTLA-4 Antigen: An inhibitory T CELL receptor that is closely related to CD28 ANTIGEN. It has specificity for CD80 ANTIGEN and CD86 ANTIGEN and acts as a negative regulator of peripheral T cell function. CTLA-4 antigen is believed to play role in inducing PERIPHERAL TOLERANCE.Interferon-gamma: The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES.Mandibular Neoplasms: Tumors or cancer of the MANDIBLE.Recombinant Proteins: Proteins prepared by recombinant DNA technology.Melanoma: A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)Neoplasm Transplantation: Experimental transplantation of neoplasms in laboratory animals for research purposes.CA-125 Antigen: Carbohydrate antigen most commonly seen in tumors of the ovary and occasionally seen in breast, kidney, and gastrointestinal tract tumors and normal tissue. CA 125 is clearly tumor-associated but not tumor-specific.Cystadenoma, Serous: A cystic tumor of the ovary, containing thin, clear, yellow serous fluid and varying amounts of solid tissue, with a malignant potential several times greater than that of mucinous cystadenoma (CYSTADENOMA, MUCINOUS). It can be unilocular, parvilocular, or multilocular. It is often bilateral and papillary. The cysts may vary greatly in size. (Dorland, 27th ed; from Hughes, Obstetric-Gynecologic Terminology, 1972)Heart Neoplasms: Tumors in any part of the heart. They include primary cardiac tumors and metastatic tumors to the heart. Their interference with normal cardiac functions can cause a wide variety of symptoms including HEART FAILURE; CARDIAC ARRHYTHMIAS; or EMBOLISM.Tumor Cells, Cultured: Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.Maxillary Neoplasms: Cancer or tumors of the MAXILLA or upper jaw.Antibodies, Protozoan: Immunoglobulins produced in a response to PROTOZOAN ANTIGENS.Polymerase Chain Reaction: In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.CD4-Positive T-Lymphocytes: A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes.Mutation: Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.Stomach Neoplasms: Tumors or cancer of the STOMACH.Bone Marrow Neoplasms: Neoplasms located in the bone marrow. They are differentiated from neoplasms composed of bone marrow cells, such as MULTIPLE MYELOMA. Most bone marrow neoplasms are metastatic.Neoplasms, Germ Cell and Embryonal: Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS.Hemagglutination Tests: Sensitive tests to measure certain antigens, antibodies, or viruses, using their ability to agglutinate certain erythrocytes. (From Stedman, 26th ed)gp100 Melanoma Antigen: A melanosome-associated protein that plays a role in the maturation of the MELANOSOME.Serologic Tests: Diagnostic procedures involving immunoglobulin reactions.CD8-Positive T-Lymphocytes: A critical subpopulation of regulatory T-lymphocytes involved in MHC Class I-restricted interactions. They include both cytotoxic T-lymphocytes (T-LYMPHOCYTES, CYTOTOXIC) and CD8+ suppressor T-lymphocytes.Lymph Nodes: They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system.Lewis Blood-Group System: A group of dominantly and independently inherited antigens associated with the ABO blood factors. They are glycolipids present in plasma and secretions that may adhere to the erythrocytes. The phenotype Le(b) is the result of the interaction of the Le gene Le(a) with the genes for the ABO blood groups.Meningeal Neoplasms: Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord.Anal Gland Neoplasms: Tumors or cancer of the anal gland.Breast Neoplasms: Tumors or cancer of the human BREAST.Antigens, CD5: Glycoproteins expressed on all mature T-cells, thymocytes, and a subset of mature B-cells. Antibodies specific for CD5 can enhance T-cell receptor-mediated T-cell activation. The B-cell-specific molecule CD72 is a natural ligand for CD5. (From Abbas et al., Cellular and Molecular Immunology, 2d ed, p156)Cytotoxicity, Immunologic: The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement.Autoantibodies: Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them.Antibodies, Helminth: Immunoglobulins produced in a response to HELMINTH ANTIGENS.Urinary Bladder Neoplasms: Tumors or cancer of the URINARY BLADDER.Neoplasm Recurrence, Local: The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.Antigens, T-Independent: Antigens which may directly stimulate B lymphocytes without the cooperation of T lymphocytes.Electrophoresis, Polyacrylamide Gel: Electrophoresis in which a polyacrylamide gel is used as the diffusion medium.Mouth Neoplasms: Tumors or cancer of the MOUTH.Antigens, CD2: Glycoprotein members of the immunoglobulin superfamily which participate in T-cell adhesion and activation. They are expressed on most peripheral T-lymphocytes, natural killer cells, and thymocytes, and function as co-receptors or accessory molecules in the T-cell receptor complex.

Glycopeptides from the surgace of human neuroblastoma cells. (1/9302)

Glycopeptides suggesting a complex oligosaccharide composition are present on the surface of cells from human neuroblastoma tumors and several cell lines derived from the tumors. The glycopeptides, labeled with radioactive L-fucose, were removed from the cell surface with trypsin, digested with Pronase, and examined by chromatography on Sephadex G-50. Human skin fibroblasts, brain cells, and a fibroblast line derived from neuroblastoma tumor tissue show less complex glycopeptides. Although some differences exist between the cell lines and the primary tumor cells, the similarities between these human tumors and animal tumors examined previously are striking.  (+info)

Immune responses to all ErbB family receptors detectable in serum of cancer patients. (2/9302)

Employing NIH3T3 transfectants with individual human ErbB receptor coding sequences as recombinant antigen sources, we detected by immunoblot analysis specific immunoreactivity against all four ErbB receptors among 13 of 41 sera obtained from patients with different types of epithelial malignancies. Overall, serum positivity was most frequently directed against ErbB2 followed by EGFR, ErbB3 and ErbB4. Specificity patterns comprised tumor patients with unique serum reactivity against ErbB2 or ErbB4. Moreover, approximately half of the positive sera exhibited concomitant reactivity with multiple ErbB receptors including EGFR and ErbB2, EGFR and ErbB4, ErbB2 and ErbB3 or EGFR, ErbB2 and ErbB3. Serum reactivity was confirmed for the respective ErbB receptors expressed by human tumor cells and corroborated on receptor-specific immunoprecipitates. Positive sera contained ErbB-specific antibodies of the IgG isotype. Representative immunohistochemical analysis of tumor tissues suggested overexpression of ErbB receptors for which serum antibodies were detectable in five of six patients. These findings implicate multiple ErbB receptors including ErbB3 and ErbB4 in addition to EGFR and ErbB2 in primary human cancer. Heterogeneity of natural ErbB-specific responses in cancer patients warrants their evaluation in light of immunotherapeutic approaches targeting these receptors.  (+info)

The role of alternative splicing of the adhesion molecule, CD44, in lymphoid malignancy. (3/9302)

AIM: To investigate the expression of CD44 isoforms containing variant exon 6 (v6) in a well characterised cohort of patients with non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukaemia (CLL), and to correlate this with phenotype and disease course. METHODS: Cryostat sections of OCT embedded diagnostic nodal material from NHL patients and cryopreserved mononuclear preparations from CLL patients were used as sources of RNA. After reverse transcription, PCR was carried out with amplimers positioned at either side of the variant exon insertion site to amplify all possible CD44 isoforms. Those isoforms containing v6 were identified after Southern blotting and hybridisation with a radiolabelled oligonucleotide. RESULTS: Of 32 NHL samples analysed, 16 did not express CD44 isoforms containing v6, six expressed an isoform containing exon v6 alone, and 10 expressed v6 long isoforms which contained exon v6 in addition to other variant exons. These data did not correlate with lymphoma classification, disease staging, or the presence or absence of extranodal disease. However, those patients expressing v6 long CD44 isoforms had a worse overall survival than those that did not. The plateau of the survival curves was 50% compared with 82%. No v6 long isoforms were detected in the 21 CLL samples investigated. CONCLUSIONS: The expression of v6 long CD44 isoforms is associated with aggressive disease in NHL, independent of grade, stage, or presence of extranodal disease.  (+info)

The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. (4/9302)

Transforming growth factor beta (TGF beta) family members are secreted in inactive complexes with a latency-associated peptide (LAP), a protein derived from the N-terminal region of the TGF beta gene product. Extracellular activation of these complexes is a critical but incompletely understood step in regulation of TGF beta function in vivo. We show that TGF beta 1 LAP is a ligand for the integrin alpha v beta 6 and that alpha v beta 6-expressing cells induce spatially restricted activation of TGF beta 1. This finding explains why mice lacking this integrin develop exaggerated inflammation and, as we show, are protected from pulmonary fibrosis. These data identify a novel mechanism for locally regulating TGF beta 1 function in vivo by regulating expression of the alpha v beta 6 integrin.  (+info)

Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. (5/9302)

Interleukin (IL)-10 is a potent immunosuppressive cytokine that has been found to be present at the tumor site in a wide variety of human cancers, including transitional cell carcinoma of the bladder. Using a murine bladder tumor (MB49), which we show to express the male transplantation antigen (HY), we tested the hypothesis that IL-10 at the tumor site can block the generation of a tumor-specific type 1 immune response. We show that, despite its expression of HY, MB49 fails to prime for an HY-specific type 1 (IFN-gamma) response in normal female mice. Although MB49 does not constitutively produce IL-10, our data support a model whereby MB49 induces infiltrating cells to produce IL-10. This feature rendered the IL-10 knockout (KO) mouse, whose infiltrating cells are incapable of IL-10 production, a suitable model in which to study MB49 in the absence of IL-10. When injected into IL-10 KO mice, MB49 does prime for an HY-specific, type 1 immune response. Furthermore, IL-10 KO mice show prolonged survival and an increased capacity to reject tumors as compared with normal mice. We also tested the ability of tumor-induced IL-10 to inhibit immunization to a non-tumor antigen present at the tumor site. When vaccinia virus encoding beta-galactosidase (beta-gal) is injected into the tumors of normal mice, no beta-gal-specific IFN-gamma response is mounted. However, when this same viral construct is injected into the tumors of IL-10 KO mice, it produces a strong beta-gal-specific, IFN-gamma response. These studies demonstrate that tumor-induced IL-10 can block the generation of a tumor-specific type 1 immune response as well as subvert attempts to elicit a type 1 immune response to a non-tumor antigen at the tumor site.  (+info)

Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. (6/9302)

Dendritic cells (DC) are critically involved in the initiation of primary immune processes, including tumor rejection. In our study, we investigated the effect of interleukin-10 (IL-10)-treated human DC on the properties of CD8(+) T cells that are known to be essential for the destruction of tumor cells. We show that IL-10-pretreatment of DC not only reduces their allostimulatory capacity, but also induces a state of alloantigen-specific anergy in both primed and naive (CD45RA+) CD8(+) T cells. To investigate the influence of IL-10-treated DC on melanoma-associated antigen-specific T cells, we generated a tyrosinase-specific CD8(+) T-cell line by several rounds of stimulation with the specific antigen. After coculture with IL-10-treated DC, restimulation of the T-cell line with untreated, antigen-pulsed DC demonstrated peptide-specific anergy in the tyrosinase-specific T cells. Addition of IL-2 to the anergic T cells reversed the state of both alloantigen- or peptide-specific anergy. In contrast to optimally stimulated CD8(+) T cells, anergic tyrosinase-specific CD8(+) T cells, after coculture with peptide-pulsed IL-10-treated DC, failed to lyse an HLA-A2-positive and tyrosinase-expressing melanoma cell line. Thus, our data demonstrate that IL-10-treated DC induce an antigen-specific anergy in cytotoxic CD8(+) T cells, a process that might be a mechanism of tumors to inhibit immune surveillance by converting DC into tolerogenic antigen-presenting cells.  (+info)

Immunologic proliferation marker Ki-S2 as prognostic indicator for lymph node-negative breast cancer. (7/9302)

BACKGROUND: Proper treatment of lymph node-negative breast cancer depends on an accurate prognosis. To improve prognostic models for this disease, we evaluated whether an immunohistochemical marker for proliferating cells, Ki-S2 (a monoclonal antibody that binds to a 100-kd nuclear protein expressed in S, G2, and M phases of the cell cycle), is an accurate indicator of prognosis. METHODS: We studied 371 Swedish women with lymph node-negative breast cancer; the median follow-up time was 95 months. The fraction of tumor cells in S phase was assessed by flow cytometry, and tumor cell proliferation was measured immunohistochemically with the monoclonal antibodies Ki-S2 and Ki-S5 (directed against the nuclear antigen Ki-67). A combined prognostic index was calculated on the basis of the S-phase fraction, progesterone receptor content, and tumor size. RESULTS: In multivariate analyses that did or did not (263 and 332 observations, respectively) include the S-phase fraction and the combined prognostic index, the Ki-S2 labeling index (percentage of antibody-stained tumor cell nuclei) emerged as the most statistically significant predictor of overall survival, disease-specific survival, and disease-free survival (all two-sided P<.0001). In the risk group defined by a Ki-S2 labeling index of 10% or less, life expectancy was not statistically significantly different from that of age-matched women without breast cancer, whereas the group with a high Ki-S2 labeling index had an increased risk of mortality of up to 20-fold. CONCLUSIONS: Cellular proliferation is a major determinant of the biologic behavior of breast cancer. Prognosis is apparently best indicated by the percentage of cells in S through M phases of the cell cycle. Measurement of the Ki-S2 labeling index of a tumor sample may improve a clinician's ability to make an accurate prognosis and to identify patients with a low risk of recurrence who may not need adjuvant therapy.  (+info)

Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers. (8/9302)

The mRNA expression of the tumor-associated antigens MAGE and GAGE was examined in 60 high-grade brain tumors. This analysis was performed by using reverse transcription-PCR, Southern blotting, and sequencing. It was demonstrated that, of the eight GAGE genes, GAGE-2 and -7 were expressed in five of seven normal brains. Four groups of tumors--adult glioblastoma multiforme (n = 20), pediatric glioblastoma multiforme (n = 9), medulloblastomas (n = 15), and ependymomas (n = 14)--were analyzed for mRNA expression. The following frequencies were observed: MAGE-1, 0, 0, 13, and 0%, respectively; MAGE-2, 5, 11, 60, and 57%; MAGE-3 & -6, 0, 0, 13, and 0%; GAGE-1, 65, 11, 13, and 43%; and GAGE-3-6 and -8: 75, 78, 47, and 93%, respectively. Two unclassified tumors expressed GAGE-3-6 and -8 only. The absence of GAGE-1 expression in normal brain, its relatively high frequency of expression in high-grade brain tumors, and its unique 3' sequence, suggest it may represent a useful target for specific immunotherapy. The detection method of reverse transcription-PCR and Southern blotting may also be useful for rapid screening of biopsy specimens both for diagnostic purposes and to determine a patient's eligibility for specific immunotherapy.  (+info)

*Monoclonal antibody therapy

Tumor cells, however are highly abnormal, and many display unusual antigens. Some such tumor antigens are inappropriate for the ... Initial research on malignant neoplasms found mAb therapy of limited and generally short-lived success with blood malignancies ... Humanised antibodies bind antigen much more weakly than the parent murine monoclonal antibody, with reported decreases in ... Increases in antibody-antigen binding strength have been achieved by introducing mutations into the complementarity determining ...

*Radioimmunotherapy

By its nature, RIT requires a tumor cell to express an antigen that is unique to the neoplasm or is not accessible in normal ... In cancer therapy, an antibody with specificity for a tumor-associated antigen is used to deliver a lethal dose of radiation to ... The ability for the antibody to specifically bind to a tumor-associated antigen increases the dose delivered to the tumor cells ... A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with ...

*List of cutaneous conditions associated with increased risk of nonmelanoma skin cancer

The most common malignant neoplasm is a basal cell carcinoma. Bolognia, Jean L.; et al. (2007). Dermatology. St. Louis: Mosby. ... List of specialized glands within the human integumentary system List of target antigens in pemphigoid List of target antigens ... in pemphigus The most common benign neoplasm that may develop within a nevus sebaceous is a syringocystadenoma papilliferum, ...

*CD2

... making it possible to use the presence of the antigen to distinguish these conditions from B cell neoplasms. Due to its ... CD2 Antigen at the US National Library of Medicine Medical Subject Headings (MeSH) Mouse CD Antigen Chart Human CD Antigen ... It has also been called T-cell surface antigen T11/Leu-5, LFA-2, LFA-3 receptor, erythrocyte receptor and rosette receptor. It ... Luzzati AL, Giacomini E, Giordani L, Pugliese O, Viora M, Chersi A (1992). "The antigen-specific induction of normal human ...

*Proliferating cell nuclear antigen

... or monoclonal antibody termed Ki-67 can be used for grading of different neoplasms, e.g. astrocytoma. They can be of diagnostic ... Proliferating cell nuclear antigen (PCNA) is a DNA clamp that acts as a processivity factor for DNA polymerase δ in eukaryotic ... PCNA was originally identified as an antigen that is expressed in the nuclei of cells during the DNA synthesis phase of the ... "Entrez Gene: PCNA proliferating cell nuclear antigen". Leonardi E, Girlando S, Serio G, Mauri FA, Perrone G, Scampini S, Dalla ...

*Topoisomerase

... may lead to secondary neoplasms in the patient.[citation needed] Topoisomerase I is the antigen recognized by Anti Scl-70 ...

*List of cutaneous neoplasms associated with systemic syndromes

List of specialized glands within the human integumentary system List of target antigens in pemphigoid List of target antigens ... Many cutaneous neoplasms occur in the setting of systemic syndromes. List of cutaneous conditions List of contact allergens ...

*Connective tissue

There are many types of connective tissue disorders, such as: Connective tissue neoplasms including sarcomas such as ... providing the ground for starting inflammatory and immune responses upon the detection of antigens. ...

*TRA (gene)

Manolios N, Kemp O, Li ZG (1994). "The T cell antigen receptor alpha and beta chains interact via distinct regions with CD3 ... Dyer MJ (1989). "T-cell receptor delta/alpha rearrangements in lymphoid neoplasms". Blood. 74 (3): 1073-83. PMID 2546634. ... Chilson OP, Kelly-Chilson AE (1989). "Mitogenic lectins bind to the antigen receptor on human lymphocytes". Eur. J. Immunol. 19 ...

*CD3 (immunology)

ISBN 1-4377-1528-1. CD3 Antigens at the US National Library of Medicine Medical Subject Headings (MeSH) Mouse CD Antigen Chart ... and can therefore be used to distinguish them from superficially similar B-cell and myeloid neoplasms. Kuby, Janis; Kindt, ... and it is at this latter stage that CD3 antigen begins to migrate to the cell membrane. The antigen is found bound to the ... The antigen remains present in almost all T-cell lymphomas and leukaemias, ...

*B-cell receptor

When a B cell is activated by its first encounter with an antigen that binds to its receptor (its "cognate antigen"), the cell ... B-cell receptor signalling is currently a therapeutic target in various lymphoid neoplasms. Seda V, Mraz M (March 2015). "B- ... Corcos D (1990). "Oncogenic potential of the B-cell antigen receptor and its relevance to heavy chain diseases and other B-cell ... B-Cell Antigen Receptors at the US National Library of Medicine Medical Subject Headings (MeSH). ...

*Thymoma-associated multiorgan autoimmunity

Thymoma is a common neoplasm arising from the thymus, the primary lymphoid organ where T cells become educated to distinguish " ... abnormal thymic education occurs as a result of subtle differences in antigen processing. In TAMA these differences result in ...

*CD4

CD1 Antigen at the US National Library of Medicine Medical Subject Headings (MeSH) Mouse CD Antigen Chart Human CD Antigen ... CD4 continues to be expressed in most neoplasms derived from T helper cells. It is therefore possible to use CD4 ... The antigen has also been associated with a number of autoimmune diseases such as vitiligo and type I diabetes mellitus. T- ... CD4 is a co-receptor of the T cell receptor (TCR) and assists the latter in communicating with antigen-presenting cells. The ...

*Neuronal lineage marker

All of these antigens are present in specific neuronal cell types. With these we can define anatomical circuits with a high ... In pathological conditions was also reported that glial neoplasms and reactive glial cells expressed this marker. Calretinin is ... Neuronal Nuclei antigen (NeuN) or Fox-3 is a nuclear protein present in postmitotic stage when start to differentiate into ... Lavezzi, A. M.; Corna, M. F.; Matturri, L. (2013). "Neuronal nuclear antigen (NeuN): a useful marker of neuronal immaturity in ...

*Plasma cell

Another important surface antigen is CD319 (SLAMF7). This antigen is expressed at high levels on normal human plasma cells. It ... Plasmacytoma, multiple myeloma, Waldenström macroglobulinemia and plasma cell leukemia are malignant neoplasms ("cancer") of ... After leaving the bone marrow, the B cell acts as an antigen presenting cell (APC) and internalizes offending antigens, which ... Pieces of the antigen (which are now known as antigenic peptides) are loaded onto MHC II molecules, and presented on its ...

*Chronic lymphocytic leukemia

Hairy cell leukemia is also a neoplasm of B lymphocytes, but the neoplastic cells have a distinct morphology under the ... Porter DL, Levine BL, Kalos M, Bagg A, June CH (2011). "Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia ... ISBN 0-7817-5007-5. Frequency of lymphoid neoplasms. (Source: Modified from WHO Blue Book on Tumour of Hematopoietic and ... "T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced ...

*List of histologic stains that aid in diagnosis of cutaneous conditions

List of specialized glands within the human integumentary system List of target antigens in pemphigoid List of target antigens ... associated with internal malignancy List of cutaneous conditions caused by mutations in keratins List of cutaneous neoplasms ... of genes mutated in cutaneous conditions List of genes mutated in pigmented cutaneous lesions List of human leukocyte antigen ...

*Epithelial cell adhesion molecule

Balzar, M; Winter MJ; de Boer CJ; Litvinov SV (October 1999). "The biology of the 17-1A antigen (Ep-CAM)". J. Mol. Med. 77 (10 ... Since EpCAM is expressed exclusively in epithelia and epithelial-derived neoplasms, EpCAM can be used as diagnostic marker for ... First discovered in 1979, EpCAM was initially described as a dominant surface antigen on human colon carcinoma. Because of its ... 1994). "Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule". The Journal of Cell Biology. 125 (2): ...

*Large-cell lung carcinoma with rhabdoid phenotype

Lung cancers are now considered a large and extremely heterogeneous family of neoplasms that feature widely varying genetic, ... Typically, markers expressed in LCLC-RP include those seen in "generic" NSCLC's, such as epithelial membrane antigen (EMA, 61 ... They also more frequently express "non-carcinomatous" markers typically associated with "dedifferentiated" neoplasms. ... rhabdoid neoplasms (i.e. those that do not contain cells containing other histological variants) Although Colby and colleagues ...

*Calreticulin

... but calreticulin is not a Ro/SS-A antigen. Earlier papers referred to calreticulin as an Ro/SS-A antigen, but this was later ... which makes CALR mutations the second most common in myeloproliferative neoplasms. All mutations (insertions or deletions) ... This association prepares the MHC class I for binding an antigen for presentation on the cell surface. Calreticulin is also ... "A human Ro/SS-A autoantigen is the homologue of calreticulin and is highly homologous with onchocercal RAL-1 antigen and an ...

*Endolymphatic sac

Neoplasms of the endolymphatic sac are very rare tumors. This article incorporates text in the public domain from the 20th ... Antigen diffusion from the perilymphatic space of the cochlea. Laryngoscope 1995; 105:623-628 Rask-Andersen H, Danckwardt- ...

*Pericyte

Hemangiopericytoma is a rare vascular neoplasm, or abnormal growth, that may either be benign or malignant. In its malignant ... During the early proliferative phase (0-12 months) the tumors express proliferating cell nuclear antigen (pericytesna), ...

*List of spiders associated with cutaneous reactions

... system List of mites associated with cutaneous reactions List of target antigens in pemphigoid List of target antigens in ... associated with internal malignancy List of cutaneous conditions caused by mutations in keratins List of cutaneous neoplasms ... cutaneous lesions List of histologic stains that aid in diagnosis of cutaneous conditions List of human leukocyte antigen ...

*Clonal hypereosinophilia

... lymphoid neoplasms, or features of both types of neoplasms. Most commonly, the present with features of myeloid neoplasms with ... It mediates at least in part the cell proliferating signaling stimulated by PDGF receptors as well as by antigen receptors on T ... Like the latter neoplasm, hematologic neoplasms cause by ETV6-JAK2 and BCR-JAK2 are aggressive and progress rapidly. Too few ... PDGFRA-associated eosinophilic neoplasms are the most common forms of clonal eosinophilia, accounting for some 40% to 50% of ...

*List of cutaneous conditions

... system List of spiders associated with cutaneous reactions List of target antigens in pemphigoid List of target antigens in ... neoplasms, and cysts are skin lesions that develop from the epidermal layer of the skin. Aberrant basal cell carcinoma ... Melanocytic nevi and neoplasms are caused by either a proliferation of (1) melanocytes, or (2) nevus cells, a form of ... an overview with emphasis on the myeloid neoplasms". Chem. Biol. Interact. 184 (1-2): 16-20. doi:10.1016/j.cbi.2009.10.009. ...

*Papillary tumors of the pineal region

Papillary tumor of the pineal region (PTPR) is a recently described neoplasm that has been formally recognized in the 2007 ... epithelial membrane antigen) → - GFAP (glial fibrillary acidic protein) → + Synaptophysin → - Chromogranin → - NSE (neuron- ... The critical diagnosis of this neoplasm is often difficult because of its similarity with other primary or secondary papillary ...
The cancer/testis antigen (CT) family is defined by its specific expression pattern. In most cases CT antigens are expressed in normal human tissue only in germline cells and some tumors. Because of their restricted expression pattern CT antigens are regarded as potential targets for vaccine immunotherapy. Little is known about the functions of the various CT antigens. Some of these CT antigens (CT 7; MAGE A3/6) seem to be involved in the dysregulation of cell-cycle control and increased cell proliferation. The monoclonal antibody Ki-A10 detects a nuclear antigen with a unique distribution pattern in normal human tissues and tumors. The antigen is now characterized as cancer/testis antigen 45 (CT45).. The accurate localisation of CT45 could provide details about its function. Therefore immunfluorescence stainings with subsequent confocal laser microscope analysis were performed to deliver precise data about the nuclear localisation of CT45. Different human tumor celllines (L428, HT1080, WS1-CLS, ...
The human 5T4 oncofoetal antigen is expressed by all types of trophoblast in pregnancy but is not detected on most adult tissues, although low levels are found on some epithelia. However, this antigen is strongly expressed by many cancers and tumour-associated labelling correlates with metastatic spread and poor clinical outcome for patients with gastric and colon cancer. Over-expression of the gene influences cell adhesion, shape and motility, which may be related to changes in the cellular localisation of the 5T4 oncofoetal antigen as malignancy develops. To establish whether the 5T4 oncofoetal antigen can serve as a tumour-specific marker for oral cancer and precancer, we have evaluated the pattern of expression on biopsies of normal, inflamed and dysplastic oral mucosa using immunohistochemistry. Oral mucosa, taken from different sites in the mouth, expressed the 5T4 oncofoetal antigen with varying intensity and pattern. The majority of the immunoreactivity was detected in the basal and ...
BioMed Research International is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies covering a wide range of subjects in life sciences and medicine. The journal is divided into 55 subject areas.
The bispecific murine monoclonal antibody (MAb) 1A10 has specificity for the human transferrin receptor (TfR) and the human tumor-associated antigen gp40. This antibody, therefore, functions as an "antigen fork" by binding to two distinct antigens on the same malignant cell. Highly purified 1A10 inhibits the growth of cells coexpressing high levels of human TfR and the tumor-associated antigen gp40 by binding to both target antigens. In SW948 cells, the majority of 1A10 binding is via its gp40 specificity, and half-maximal inhibition of cell growth by 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay requires 20-30-μg/ml concentrations of 1A10. The binding of 1A10 correlates with growth inhibition in the cell lines HT-29, SK-OV-3, OVCAR-2, and OVCAR-3. The growth of OVCAR-10 cells, which express little gp40 and TfR, is not inhibited by 1A10. However, SK-BR-3 cells, which express abundant gp40 and extremely high levels of TfR, are insensitive to the effects of 1A10. In some ...
Haughton, G; Lanier, L L.; Babcock, G F.; Lynes, D M.; and willexploit, N., "Ation of the surface idiotype as tumor specific antigen." (1978). Subject Strain Bibliography 1978. 2066 ...
Liang, W and Cohen, E P., "Detection of thymus leukemia antigens on the surface membranes of murine leukemia cells resistant to thymus leukemia anti- bodies and guinea pig complement." (1977). Subject Strain Bibliography 1977. 2311 ...
As a leading supplier of innovative life science research tools, Creative Diagnostics continues to expand its products portfolio by offering of unique antigens for researchers globally, which is supported by extensive research, development, and validation for superior quality. The addition of antigen products and services will enable scientists to work on more specific projects, and also provide leading researchers and diagnostic manufacturers with a more diverse antigen selection, which facilitates the development of assays with greater specificity and sensitivity.. These newly released antigens are rigorously tested to meet the demand in research and development and are featured with excellent quality, including Viral Antigens, Bacterial Antigens, Fungal Antigens, Parasitic Antigens, Immunoglobulin, Hapten, Cardiac Biomarkers and so on. With this expanded offering of antigens products, Creative Diagnostics enables scientists to achieve more complete analysis experiments. These products along ...
The observation that many tumor-associated antigens are nonmutated "self-antigens" has raised the question of how to induce large numbers of highly active, self/tumor antigen-specific T cells capable of destroying large, established tumors. Nonmutated self-antigens are particularly attractive targets for immunotherapy, because they are shared among patients, obviating the need for personalized vaccine development (1-6). We and others have attempted numerous vaccination approaches targeting self/tumor antigens. However, despite the increased numbers of self/tumor antigen-specific T cells, the reproducible induction of significant destruction of large, established cancers in mouse or in man using any self-antigen vaccine-based approach remains an elusive goal (7-9). A state of functional tolerance apparently exists in the tumor-bearing host.. This state of functional tolerance, defined here as the coexistence of tumor-specific T cells and growing tumor cells, may be incomplete. There is evidence ...
EpCAM is a widely described tumor-associated antigen, stem cell and cancer stem cell marker [4, 22-24]. Cancer stem cells with a high EpCAM expression are considered to be more malignant and more prone to give metastasis than those with a low expression [24, 25]. Although EpCAM overexpression in breast cancer is correlated with aggressive behavior and decreased overall survival of patients [13, 25-27], functions and effects of EpCAM overexpression in normal mammary epithelial cells, i.e. healthy tissue have not been described so far.. In normal breast epithelia EpCAM has a strict basolateral expression. Among all epithelial cell-types only myoepithelial cells are EpCAM-negative [28]. Tumor cells loosing cell-cell contacts and invading host tissue are also loosing the strict basolateral distribution of EpCAM and show more cytoplasmic and membranous staining [5, 27]. Whether this is mediated by loss of cell polarity or by generation of translocated EpCAM isoforms is still under investigation [5, ...
In developed countries, colorectal cancer (CRC) is a leading cause of cancer. Because this disease develops slowly over years and often starts with the apparition of polyps that may evolve in a malignant tumor, this cancer is particularly suitable for screening. However, current techniques of detection lack specificity and sensitivity, or are invasive, reducing the compliance of the patients. Thus, there is a need to find new biomarkers to improve the detection of CRC at an early stage and to reduce its incidence. In this work, we focused on autoantibodies (aAb) produced by the immune system as potential CRC biomarkers since they combine several advantages including stability, specificity and early production in the course of the disease. Human tumor-associated antigens (TAA) of interest were identified by the serological proteome analysis (SERPA) approach, based on the combination of 2D-gel electrophoresis and after transfer onto membranes, immunoblotting with sera from tumor-bearing mice or ...
Compare Cancer/Testis Antigen Family 45, Member A2 ELISA Kits from leading suppliers on Biocompare. View specifications, prices, citations, reviews, and more.
Abstract Background The lack of sufficient specificity and sensitivity among conventional cancer biomarkers, such as prostate specific antigen (PSA) for prostate cancer has been widely recognized after several decades of clinical implications. Autoantibodies (autoAb) among others are being extensively investigated as potential substitute markers, but remain elusive. One major obstacle is the lack of a sensitive and multiplex approach for quantifying autoAb against a large panel of clinically relevant tumor-associated antigens (TAA). Methods To circumvent preparation of phage lysates and purification of recombinant proteins, we identified B cell epitopes from a number of previously defined prostate cancer-associated antigens (PCAA). Peptide epitopes from cancer/testis antigen NY-ESO-1, XAGE-1b, SSX-2,4, as well as prostate cancer overexpressed antigen AMACR, p90 autoantigen, and LEDGF were then conjugated with seroMAP microspheres to allow multiplex measurement of autoAb present in serum samples. ...
Mass spectrometry helps identify antigens on tumor cells - posted in Immunology Products: Using an analytical technique called mass spectrometry (MS) that helps identify the chemical constitution of a substance, Angela M. Krackhardt and colleagues from Technische Universitat Munchen and collaborators identify novel target antigens for cancer intervention. Michal Bassani-Sternberg from Max Planck Institute of Biochemistry is the first author. CusAb offers protein. Immunotherapy works...
Alt. Names/Synonyms: ACSTD1; Adenocarcinoma-associated antigen; carcinoma-associated antigen GA733-2; Cell surface glycoprotein Trop-1; CO-17A; CO17-1A; DIAR5; EGP; EGP-2; EGP314; EGP34; EGP40; Ep-CAM; EPCAM; Epithelial cell adhesion molecule; Epithelial cell surface antigen; Epithelial glycoprotein; Epithelial glycoprotein 314; ESA; GA733-2; hEGP-2; hEGP314; HNPCC8; human epithelial glycoprotein-2; KS 1/4 antigen; KS1/4; KSA; M1S2; M4S1; Major gastrointestinal tumor-associated protein GA733-2; membrane component, chromosome 4, surface marker (35kD glycoprotein); MIC18; MK-1; TACST-1; TACSTD1; TROP1; Tumor-associated calcium signal transducer 1 ...
Cancer treatment vaccines are designed to treat cancers that have already developed rather than to prevent them in the first place. Cancer treatment vaccines contain cancer-associated antigens to enhance the immune systems response to a patients tumor cells. The cancer-associated antigens can be proteins or another type of molecule found on the surface of or inside cancer cells that can stimulate B cells or killer T cells to attack them.. Some vaccines that are under development target antigens that are found on or in many types of cancer cells. These types of cancer vaccines are being tested in clinical trials in patients with a variety of cancers, including prostate, colorectal, lung, breast, and thyroid cancers. Other cancer vaccines target antigens that are unique to a specific cancer type (7-14). Still other vaccines are designed against an antigen specific to one patients tumor and need to be customized for each patient. The one cancer treatment vaccine that has received FDA approval, ...
PURPOSE: NY-ESO-1, one of the most immunogenic tumor antigens, is expressed in 15% to 25% of metastatic prostate cancers. The immunological and clinical effects of vaccination with recombinant NY-ESO-1 protein combined with CpG as adjuvant were evaluated. EXPERIMENTAL DESIGN: In a phase I clinical study, patients with advanced prostate cancer were vaccinated with recombinant NY-ESO-1 protein (100 μg) mixed with CpG 7909 (2.5 mg) every 3 weeks intradermally for 4 doses. Objectives of the study were the safety of the vaccine and changes of specific humoral and cellular immunological responses to NY-ESO-1 in relation to detectable NY-ESO-1 expression in the individual tumor. RESULTS: All 12 baseline sero-negative patients developed high-titer NY-ESO-1 antibody responses. B-cell epitope mapping identified NY-ESO-1 p91-110 to be recognized most frequently by vaccine-induced antibodies. Two patients developed significant antibody titers against the adjuvant CpG. NY-ESO-1-specific CD4+ and/or CD8+ ...
Cancer-Testis Antigens: -Smart- Biomarkers for Diagnosis and Prognosis of Prostate and Other Cancers. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
The isolation of CD8+ cytolytic T cells (CTL) reactive to the autologous tumors in cancer patients has allowed, during the last decade, the identification of several categories of tumor-associated antigens that can be the target of tumor-specific immune responses. Among them, one of the most relevant for the development of cancer vaccines is the group of the so-called Cancer-Testis (CT) antigens, which are expressed by tumor cells but not by most somatic adult tissues, with the exception of testis. Because of their expression commonly found in tumors of various histological types, CT antigen-derived peptides recognized by tumor reactive CTL are relevant candidates for generic vaccination of cancer patients.. In the last two years, we have analyzed the natural response to four CT antigen-derived HLA-A2 restricted epitopes recognized by tumor reactive CTL. Three of them correspond to the previously described peptides from MAGE-A10 (254-262), NY-ESO-1 (157-165) and CAMEL (1-11). The fourth peptide ...
In this issue of Clinical Cancer Research, a new development in adoptive T-cell therapy experimental mouse tumor model is reported by Leisegang and colleagues (1).. In retrospect, the 1990s were considered a golden period for tumor immunology when many tumor antigens recognized by T cells were identified. The antigens reported by Boon and colleagues in both murine and human cancers (2, 3) were derived from genes that are overexpressed in cancer and fetal tissues (4). The second class of unmutated antigens recognized by tumor-reactive T cells is tissue-specific antigens that are also found in tumor cells (5). These unmutated tumor antigens were favored for cancer vaccines and cancer therapy because they are present in a high proportion of human cancers. However, the classical study by Prehn and Main (6) has cast a long shadow on the utility of the shared tumor antigen, as their in vivo analysis showed that tumor rejection antigens are by and large individually specific. In supporting this notion, ...
Preferentially expressed antigen in melanoma (PRAME) is a cancer-testis antigen that is expressed in many cancers and leukemias. In healthy tissue, PRAME expression is limited to the testes and ovaries, making it a highly attractive cancer target. PRAME is an intracellular protein that cannot currently be drugged. After proteasomal processing, the PRAME300-309 peptide ALYVDSLFFL (ALY) is presented in the context of human leukocyte antigen HLA-A*02:01 molecules for recognition by the T cell receptor (TCR) of cytotoxic T cells. Here, we have described Pr20, a TCR mimic (TCRm) human IgG1 antibody that recognizes the cell-surface ALY peptide/HLA-A2 complex. Pr20 is an immunological tool and potential therapeutic agent. Pr20 bound to PRAME+HLA-A2+ cancers. An afucosylated Fc form (Pr20M) directed antibody-dependent cellular cytotoxicity against PRAME+HLA-A2+ leukemia cells and was therapeutically effective against mouse xenograft models of human leukemia. In some tumors, Pr20 binding markedly ...
Preferentially expressed antigen in melanoma (PRAME) is a cancer-testis antigen that is expressed in many cancers and leukemias. In healthy tissue, PRAME expression is limited to the testes and ovaries, making it a highly attractive cancer target. PRAME is an intracellular protein that cannot currently be drugged. After proteasomal processing, the PRAME300-309 peptide ALYVDSLFFL (ALY) is presented in the context of human leukocyte antigen HLA-A*02:01 molecules for recognition by the T cell receptor (TCR) of cytotoxic T cells. Here, we have described Pr20, a TCR mimic (TCRm) human IgG1 antibody that recognizes the cell-surface ALY peptide/HLA-A2 complex. Pr20 is an immunological tool and potential therapeutic agent. Pr20 bound to PRAME+HLA-A2+ cancers. An afucosylated Fc form (Pr20M) directed antibody-dependent cellular cytotoxicity against PRAME+HLA-A2+ leukemia cells and was therapeutically effective against mouse xenograft models of human leukemia. In some tumors, Pr20 binding markedly ...
Preferentially expressed antigen in melanoma (PRAME) is a cancer-testis antigen that is expressed in many cancers and leukemias. In healthy tissue, PRAME expression is limited to the testes and ovaries, making it a highly attractive cancer target. PRAME is an intracellular protein that cannot currently be drugged. After proteasomal processing, the PRAME300-309 peptide ALYVDSLFFL (ALY) is presented in the context of human leukocyte antigen HLA-A*02:01 molecules for recognition by the T cell receptor (TCR) of cytotoxic T cells. Here, we have described Pr20, a TCR mimic (TCRm) human IgG1 antibody that recognizes the cell-surface ALY peptide/HLA-A2 complex. Pr20 is an immunological tool and potential therapeutic agent. Pr20 bound to PRAME+HLA-A2+ cancers. An afucosylated Fc form (Pr20M) directed antibody-dependent cellular cytotoxicity against PRAME+HLA-A2+ leukemia cells and was therapeutically effective against mouse xenograft models of human leukemia. In some tumors, Pr20 binding markedly ...
Preferentially expressed antigen in melanoma (PRAME) is a cancer-testis antigen that is expressed in many cancers and leukemias. In healthy tissue, PRAME expression is limited to the testes and ovaries, making it a highly attractive cancer target. PRAME is an intracellular protein that cannot currently be drugged. After proteasomal processing, the PRAME300-309 peptide ALYVDSLFFL (ALY) is presented in the context of human leukocyte antigen HLA-A*02:01 molecules for recognition by the T cell receptor (TCR) of cytotoxic T cells. Here, we have described Pr20, a TCR mimic (TCRm) human IgG1 antibody that recognizes the cell-surface ALY peptide/HLA-A2 complex. Pr20 is an immunological tool and potential therapeutic agent. Pr20 bound to PRAME+HLA-A2+ cancers. An afucosylated Fc form (Pr20M) directed antibody-dependent cellular cytotoxicity against PRAME+HLA-A2+ leukemia cells and was therapeutically effective against mouse xenograft models of human leukemia. In some tumors, Pr20 binding markedly ...
Principal Investigator:ARAKI Nobuhito, Project Period (FY):1995 - 1997, Research Category:Grant-in-Aid for Scientific Research (C), Section:一般, Research Field:Orthopaedic surgery
Three of nine patients (33%) remain in complete clinical remission at 25, 38, and 52 months, respectively. The cancer-testis antigen NY-ESO-1 is expressed in greater than 40% of advanced epithelial ovarian cancers and represents a promising immunotherapeutic target. In a small Phase I (safety and immunogenicity) clinical trial conducted by Memorial Sloan-Kettering Cancer Center and…
There is clear evidence that tumor patients are able to generate TAA-specific T cell immunity spontaneously. Whereas the presence of tumor-specific T cells has been shown by many groups and for various tumor types, much less is known about the function of TAA-specific T cells in vivo. Most of the TAAs including differentiation, germ-line, and shared overexpressed antigens are not tumor specific but are also expressed at low levels in certain nonmalignant tissues. This should influence the type of T cell response because deletion of functional high-avidity self-reactive T cells in the thymus as well as peripheral deletion or anergy was shown in various animal models (reviewed in Ref. 74 ). There are a few recent studies analyzing the functional avidity of TAA-specific T cells in patients. In leukemia patients, low-avidity T cells to proteinase 3, which are able to kill leukemia cells, can readily be expanded. However, high-avidity T cells can also be expanded from patients in cytogenetic ...
Adoptive transfer of T cell receptor-engineered (TCR-engineered) T cells is a promising approach in cancer therapy but needs improvement for more effective treatment of solid tumors. While most clinical approaches have focused on CD8+ T cells, the importance of CD4+ T cells in mediating tumor regression has become apparent. Regarding shared (self) tumor antigens, it is unclear whether the human CD4+ T cell repertoire has been shaped by tolerance mechanisms and lacks highly functional TCRs suitable for therapy. Here, TCRs against the tumor-associated antigen NY-ESO-1 were isolated either from human CD4+ T cells or from mice that express a diverse human TCR repertoire with HLA-DRA/DRB1*0401 restriction and are NY-ESO-1 negative. NY-ESO-1-reactive TCRs from the mice showed superior recognition of tumor cells and higher functional activity compared with TCRs from humans. We identified a candidate TCR, TCR-3598_2, which was expressed in CD4+ T cells and caused tumor regression in combination with ...
Adoptive transfer of T cell receptor-engineered (TCR-engineered) T cells is a promising approach in cancer therapy but needs improvement for more effective treatment of solid tumors. While most clinical approaches have focused on CD8+ T cells, the importance of CD4+ T cells in mediating tumor regression has become apparent. Regarding shared (self) tumor antigens, it is unclear whether the human CD4+ T cell repertoire has been shaped by tolerance mechanisms and lacks highly functional TCRs suitable for therapy. Here, TCRs against the tumor-associated antigen NY-ESO-1 were isolated either from human CD4+ T cells or from mice that express a diverse human TCR repertoire with HLA-DRA/DRB1*0401 restriction and are NY-ESO-1 negative. NY-ESO-1-reactive TCRs from the mice showed superior recognition of tumor cells and higher functional activity compared with TCRs from humans. We identified a candidate TCR, TCR-3598_2, which was expressed in CD4+ T cells and caused tumor regression in combination with ...
Adoptive transfer of T cell receptor-engineered (TCR-engineered) T cells is a promising approach in cancer therapy but needs improvement for more effective treatment of solid tumors. While most clinical approaches have focused on CD8+ T cells, the importance of CD4+ T cells in mediating tumor regression has become apparent. Regarding shared (self) tumor antigens, it is unclear whether the human CD4+ T cell repertoire has been shaped by tolerance mechanisms and lacks highly functional TCRs suitable for therapy. Here, TCRs against the tumor-associated antigen NY-ESO-1 were isolated either from human CD4+ T cells or from mice that express a diverse human TCR repertoire with HLA-DRA/DRB1*0401 restriction and are NY-ESO-1 negative. NY-ESO-1-reactive TCRs from the mice showed superior recognition of tumor cells and higher functional activity compared with TCRs from humans. We identified a candidate TCR, TCR-3598_2, which was expressed in CD4+ T cells and caused tumor regression in combination with ...
Background: This study aimed to assess the prognostic value of receptor binding cancer antigen expressed on SiSo cells (RCAS1) expression and host immune response in gastric carcinomas. Methods: We i
ASN004 is an Antibody Drug Conjugate (ADC) that targets the 5T4 oncofetal antigen (trophoblast glycoprotein), which is highly expressed in a wide range of malignant tumors, while having very limited expression in normal tissues. ASN004 incorporates a novel single-chain homo-dimer antibody, Fleximer® linker technology (Mersana Therapeutics), and several cytotoxic dolastatin (auristatin) analog warheads per ADC molecule (drug/antibody ratio ∼15). ASN004 shows high affinity for the 5T4 antigen and for 5T4-expressing tumor cells. As well, ASN004 shows potent cytotoxicity that is selective for 5T4-expressing tumor cells. ASN004 provides strong tumor regression and tumor-free survivors in multiple tumor xenograft models, at well-tolerated doses as low as 0.3 mg/kg iv. Furthermore, ASN004 causes tumor regression when administered to xenografts bearing more advanced (500 mm3) tumors. Robust, potent efficacy for ASN004 has also been demonstrated in head-to-head comparison studies with relevant ...
As mentioned earlier, another aspect of cancer is a failure of the immune system to recognize tumor specific antigens. Cytokines behave similarly to growth factors, causing cells to grow and divide; however, they are the predominant cellular signals of the immune system and have other actions such as attaching (chemotaxis) white blood cells to the site of an infection. Interestingly, it has been shown cancer cells signal suppressor T cells to protect them from killer T cells against unique tumor antigens. The mechanism of recruitment is not fully understood but TGF-b and interleukin 10 (IL-10) have been implicated in regulatory T cell function. While some cytokines play a role in suppressing the immune system, others such as IL-2 play a role in activating the immune system. One of the strategies in battling cancer has been to exploit the ability of interleukin-2 (IL-2) to heighten the immune response. IL-2 has been shown to cause complete remission in 6% of patients with renal cancer ...
We have shown that both regressor and progressor clones can be isolated from a UV regressor tumor, RD-1024. Although the daughter clones are characterized by differences in tumorigenic potential in normal transplant hosts, they nevertheless seem to express the same major tumor rejection antigens, because immunization with either the regressor parent tumor, RD-1024, or with regressor Cl 8 protects against subsequent challenge with progressor C1 4 or Cl 9. Consistent with the in vivo-generated data is the evidence that draining lymph node cells with functional specificity for regressor Cl 8 are capable of cross-reactive cytotoxicity in an in vitro chromium release assay. We have demonstrated an indirect interaction occurring in vivo between regressor and progressor cells, in that Cl 8 cells have the ability to influence the outcome of simultaneous or sequential challenge with Cl 4 or Cl 9 cells. Because 500 rad of gamma irradiation has been shown to compromise the ability of mice to respond to a ...
Tikcro Technologies Ltd., powered by a novel 3D antigen design technology, generates new ‎antibodies that block receptor/ligand surface domains of immune modulators and re-‎activate the bodys immune system to fight cancer. Our antibodies are in various pre-‎clinical stages.. Following extensive collaborative research with the Weizmann Institute of Science in ‎Israel, we are developing drug-candidates by leveraging a unique antigen design ‎technology for the generation of new functional blocking antibodies. This approach has ‎shown early success with pipeline below. Going forward, in 2017-2018 we plan to advance ‎with early-stage candidates to rigorous pre-clinical trials and aim to build sufficient data for ‎further progress and clinical trials.‎. ...
Janelle, Valérie; Lamarre, Alain (2014). How Informative is the Immune Response Against Surrogate Tumor Antigens to Assess Antitumor Immunity? Frontiers in oncology , vol. 4 , nº 135. p. 1-3. DOI: 10.3389/fonc.2014.00135. ...
TROP2 belongs to the TACSTD family and is a cell surface glycoprotein encoded by the TACSTD2 gene. It is also known as tumor-associated calcium signal transducer 2 (TACSTD2), epidermal glycoprotein 1 (EGP-1), and gastrointestinal tumor-associated antigen (GA733-1) and surface mar
Squamous cell carcinoma antigen: a role in the early identification of nodal metastases in men with squamous cell carcinoma of the penis. To evaluate whether serum squamous cell carcinoma antigen (SCCAg) measurements may be of use in identifying nodal metastases in patients with SCC of the penis after treating the primary tumour. The levels of SCCAg were analysed in 11 men with penile SCC between 1994 and 2001. An elevated SCCAg level had a sensitivity of 57% (95% confidence interval, CI, 18-90%) and a specificity of 100% (CI 40-100%) for nodal metastases. Levels of SCCAg increased exponentially in patients who developed nodal metastases after treatment of the primary tumour, and were elevated before clinical or radiological evidence of nodal disease. Either the absolute level or the rate of rise of SCCAg may be a useful tool with which to follow patients after excision of the primary tumour. It may be more sensitive than computed tomography and magnetic resonanc imaging in detecting recurrence, ...
Our analysis of cervical cancer patients treated with CCRT indicated that the sensitivity and specificity of two consecutive increases in serum SCC-Ag for predicting tumor recurrence were 61.1% and 97.9%, respectively. These results are comparable to previously reported results. For example, several studies of cervical cancer patients showed that an elevated serum SCC-Ag level was associated with 70-92% rate of recurrent tumors [8, 11, 14-19]; in addition, the specificity of SCC-Ag during the follow-up period was quite high, varying from 95 to 98% [7, 16, 20]. According to our ROC analysis, the area under the ROC curve indicated the ΔSCC-Ag was 0.83 for patients who had elevated pre-treatment SCC-Ag. Therefore, our results indicate that ΔSCC-Ag had good clinical performance in detection of recurrent disease.. As described above, we defined biochemical failure as two consecutive SCC-Ag values above normal. There are no standard criteria used to define biochemical failure in cervical cancer, and ...
TY - JOUR. T1 - Carbonic anhydrase IX expression in renal neoplasms. T2 - Correlation with tumor type and grade. AU - Genega, Elizabeth M.. AU - Ghebremichael, Musie. AU - Najarian, Robert. AU - Fu, Yineng. AU - Wang, Yihong. AU - Argani, Pedram. AU - Grisanzio, Chiara. AU - Signoretti, Sabina. PY - 2010/12. Y1 - 2010/12. N2 - Carbonic anhydrase IX (CAIX), a hypoxia-induced protein, is expressed in some renal tumors. We evaluated its immunohistochemical expression in 317 primary and 42 metastatic renal neoplasms (186 clear cell, 52 papillary, 35 chromophobe, 47 unclassified, and 15 Xp11.2 translocation renal cell carcinomas [RCCs]; 26 oncocytomas; 2 metanephric adenomas; 1 urothelial carcinoma; 1 mixed epithelial and stromal tumor; and 1 angiomyolipoma); 7 neoplasms were unknown as to whether they were primary or metastatic. We also correlated expression with tumor type and grade. Variable staining was seen in clear cell, papillary, unclassified, and Xp11.2 translocation carcinomas. One ...
TY - JOUR. T1 - Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12. AU - Mortarini, Roberta. AU - Borri, Alessandra. AU - Tragni, Gabrina. AU - Bersani, Ilaria. AU - Vegetti, Claudia. AU - Bajetta, Emilio. AU - Pilotti, Silvana. AU - Cerundolo, Vincenzo. AU - Anichini, Andrea. PY - 2000/7/1. Y1 - 2000/7/1. N2 - Systemic effects on T-cell-mediated antitumor immunity, on expression of T-cell adhesion/homing receptors, and on the promotion of T-cell infiltration of neoplastic tissue may represent key steps for the efficacy of immunological therapies of cancer. In this study, we investigated whether these processes can be promoted by s.c. administration of low-dose (0.5 μg/kg) recombinant human interleukin-12 (rHuIL-12) to metastatic melanoma patients. A striking burst of HLA-restricted CTL precursors (CTLp) directed to autologous tumor was documented in peripheral blood by a ...
The protein encoded by this gene is an RNA-binding nuclear protein that is a tumor-rejection antigen. This antigen possesses tumor epitopes capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes in cancer patients and may be useful for specific immunotherapy. This gene product is found to be an important cellular factor for HIV-1 gene expression and viral replication. It also associates transiently with U6 and U4/U6 snRNPs during the recycling phase of the spliceosome cycle. This encoded protein is thought to be involved in the regulation of mRNA splicing. [provided by RefSeq, Jul 2008 ...
TY - JOUR. T1 - Surface Marker Epithelial Cell Adhesion Molecule and E-cadherin Facilitate the Identification and Selection of Induced Pluripotent Stem Cells. AU - Chen, Hsin Fu. AU - Chuang, Ching Yu. AU - Lee, Wen Chih. AU - Huang, Hsiang Po. AU - Wu, Han Chung. AU - Ho, Hong Nerng. AU - Chen, Yu Ju. AU - Kuo, Hung Chih. PY - 2011/9/1. Y1 - 2011/9/1. N2 - The derivation of induced pluripotent stem cells (iPSCs) requires not only efficient reprogramming methods, but also reliable markers for identification and purification of iPSCs. Here, we demonstrate that surface markers, epithelial cells adhesion molecule (EpCAM) and epithelial cadherin (E-cadherin) can be used for efficient identification and/or isolation of reprogrammed mouse iPSCs. By viral transduction of Oct4, Sox2, Klf4 and n- or c-Myc into mouse embryonic fibroblasts, we observed that the conventional mouse embryonic stem cell (mESC) markers, alkaline phosphatase (AP) and stage-specific embryonic antigen 1 (SSEA1), were expressed in ...
Buy Psca recombinant protein, Prostate stem cell antigen Recombinant Protein-P57096.1 (MBS962351) product datasheet at MyBioSource, Recombinant Proteins
6042 Introduction: The majority of human tumor-associated antigens (TAAs) are either minimally altered or malexpressed "self" antigens. Effective anti-tumor immunity must overcome intrinsic tolerance to TAAs and barriers derived from host:tumor interactions to mount a sufficiently potent anti-tumor immune response for tumor cell destruction. The immune system dendritic cell (DC), the most potent antigen-presenting cell, is a logical target for strategies designed to elicit robust immune responses. However, adoptive transfer of ex vivo manipulated DCs must overcome biological and regulatory hurdles. The Venezuelan Equine Encephalitis (VEE)-derived replicon particle (VRP) has in vivo tropism for murine DCs and may be advantageous for eliciting larger magnitude and more efficacious anti-tumor immune responses. Methods: These studies used VRPs encoding the reporter protein dsRed (VRP-dsRed), rat neu target antigen (VRP-rNeu) or an irrelevant antigen influenza hemagglutinin (VRP-HA) and a stringent ...
As a leading supplier of innovative life science research tools, Creative Diagnostics continues to expand its products portfolio by offering of unique antigens for researchers globally, which is supported by extensive research, development, and validation for superior quality. The addition of antigen products and services will enable scientists to work on more specific projects, and also provide leading researchers and diagnostic manufacturers with a more diverse antigen selection, which facilitates the development of assays with greater specificity and sensitivity.. These newly released antigens are rigorously tested to meet the demand in research and development and are featured with excellent quality, including Viral Antigens, Bacterial Antigens, Fungal Antigens, Parasitic Antigens, Immunoglobulin, Hapten, Cardiac Biomarkers and so on. With this expanded offering of antigens products, Creative Diagnostics enables scientists to achieve more complete analysis experiments. These products along ...
Background: The delivery of specific immunotherapies for malignant tumours requires the identification of relevant tumour antigens and sequences from these which can be used to stimulate protective T cell-mediated immunity. HAGE (DDX43) is a cancer testis antigen belonging to the DEAD box family of helicases found by our group to be over-expressed in many solid cancers including breast cancer (Mathieu et al.1) immunogenic (Mathieu et al.2 and to be a biomarker for poor prognosis as well as a predictor of chemotherapy response in breast cancer (Abdel-fatah et al.3). We propose that HAGE might be a novel immunotherapeutic target for patients bearing breast cancers expressing this antigen. The aim of this study is to identify strongly immunogenic HAGE-derived sequences which can be used for the development of a therapeutic vaccine for HAGE positive cancer.. Experimental Design: The HAGE-derived sequences were identified and assessed after: (i) using a computer-based epitope predictive tool; (ii) ...
Human melanoma antigen (MAGE) genes have been shown to be expressed in both normal tissues and in various tumors and tumor related cells. Two types of MAGE genes have been characterized based on their expression: type-I members are silent in all normal tissues except for in the male germ line and placenta while type-II members are expressed ubiquitously in both tumor and normal cells (Figure 1). MAGE-C subfamily members are type-I genes expressed in various tumor types; their proteins are tumor-specific antigens that can be recognized by cytolytic T lymphocytes. MAGE-D subfamily members are type-II members they do not encode for those tumor-specific antigens seen in type-I MAGE and are also expressed ubiquitously in normal adult tissues. While MAGE genes could be targets for immunotherapy, information on the function and expression pattern of MAGE-C and MAGE D genes, however, remains incomplete. Analysis of the gene expression of type-I and type-II MAGE genes in various histological tumors may ...
Epithelial cell adhesion molecule (EpCAM) is a transmembrane glycoprotein mediating Ca2+-independent homotypic cell-cell adhesion in epithelia. EpCAM is also involved in cell signaling, migration, proliferation, and differentiation. Additionally, EpCAM has oncogenic potential via its capacity to upregulate c-myc, e-fabp, and cyclins A & E. Since EpCAM is expressed exclusively in epithelia and epithelial-derived neoplasms, EpCAM can be used as diagnostic marker for various cancers. It appears to play a role in tumorigenesis and metastasis of carcinomas, so it can also act as a potential prognostic marker and as a potential target for immunotherapeutic strategies. First discovered in 1979, EpCAM was initially described as a dominant surface antigen on human colon carcinoma. Because of its prevalence on many carcinomas, it has been "discovered" many different times. EpCAM therefore has many aliases the most notable of which include TACSTD1 (tumor-associated calcium signal transducer 1), CD326 ...
A discovery by scientists working with the Health Sciences Initiative could lead the way to a vaccine against prostate cancer. The researchers, led by immunologist James Allison, a Howard Hughes Medical Institute investigator and professor of molecular and cell biology, found a protein on prostate cancer cells that tips off the immune system to the tumor s presence and brings in an armada of immune cells to destroy it.. If the protein, called an antigen, is truly unique to prostate cancer cells, it could lead to diagnostics for prostate cancer and a potential vaccine therapy against the disease, which is the second leading cause of cancer death in men, after lung cancer. This is the first prostate cancer antigen found.. The hope is twofold, Allison said. One, knowing what the specific target of the immune system is, we can do some very direct studies of whether it is a prognosticator of favorable outcome of disease. And two, we can start thinking about using the antigens to develop a specific ...
Because tumor-specific cytotoxic T lymphocytes (CTL) recognize tumor antigen associated with MHC class I molecules expressed on the tumor surface, any alteration in the tumor antigen processing and presentation will greatly affect CTL immunity. In fact, downregulation or complete loss of MHC I molecules have been demonstrated in a wide array of tumors, particularly prostate, colon, lung, and breast cancers (5-12). Disruption or downregulation of antigen processing components, such as TAP (transporters associated with antigen processing) and LMP (components of the proteasome complex) genes have also been observed in several tumor types, including breast, prostate, and renal cancers (13-15). Another tactic tumors exploit is downregulation or alteration of tumor antigens. Several independent research groups described the loss of melanoma-associated antigen either during treatment by adoptive transfer of ex vivo expanded antigen-specific CTL (16) or during immune therapy by tumor vaccinations ...
Abstract Epithelial cell adhesion molecule (EpCAM, CD326) is a pleiotropic molecule that potentially offers therapeutic applications in cancer treatment. Initially described as a d..
NY-ESO-1 is a human tumor antigen of the cancer/testis family. It is highly expressed in many poor-prognosis melanomas. It is being studied as possible target for a cancer vaccine or immunotherapy. It is a target for some experimental engineered T-cell therapies for myeloma. Lloyd J. Old#Major Discoveries Gnjatic, S; et al. (2006). "NY-ESO-1: review of an immunogenic tumor antigen". Advances in Cancer Research. 95: 1-30. doi:10.1016/S0065-230X(06)95001-5. PMID 16860654. van Rhee, F (15 May 2005). "NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses" (PDF). Blood. 105 (10): 3939-3944. doi:10.1182/blood-2004-09-3707. PMC 1895070 . PMID 15671442. Rapoport, AP; et al. (20 July 2015). "NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma". Nature Medicine. 21 (8): 914-921. doi:10.1038/nm.3910. PMC 4529359 . PMID 26193344. A novel human-derived antibody against NY-ESO-1 ...
Clemetson, K J.; Gerber, A; Bertschmann, M; and Luscher, E F., "Solubilization of histocompatibility and tumour-associated antigens of the p-815 murine mastocytoma cell." (1976). Subject Strain Bibliography 1976. 1795 ...
0192] Numerous tumor antigens are known in the art, including: (a) cancer-testis antigens such as NY-ESO-1, SSX2, SCP1 as well as RAGE, BAGE, GAGE and MAGE family polypeptides, for example, GAGE-1, GAGE-2, MAGE-1, MAGE-2, MAGE-3, MAGE-4, MAGE-5, MAGE-6, and MAGE-12 (which can be used, for example, to address melanoma, lung, head and neck, NSCLC, breast, gastrointestinal, and bladder tumors), (b) mutated antigens, for example, p53 (associated with various solid tumors, e.g., colorectal, lung, head and neck cancer), p21/Ras (associated with, e.g., melanoma, pancreatic cancer and colorectal cancer), CDK4 (associated with, e.g., melanoma), MUM1 (associated with, e.g., melanoma), caspase-8 (associated with, e.g., head and neck cancer), CIA 0205 (associated with, e.g., bladder cancer), HLA-A2-R1701, beta catenin (associated with, e.g., melanoma), TCR (associated with, e.g., T-cell non-Hodgkins lymphoma), BCR-abl (associated with, e.g., chronic myelogenous leukemia), triosephosphate isomerase, KIA ...
Treatment with the demethylating agent 5-Azacytidine leads to prolonged survival for patients with myelodysplastic syndrome, and the demethylation induces upregulation of cancer-testis antigens. Cancer-testis antigens are well-known targets for immune recognition in cancer, and the immune system may have a role in this treatment regimen. We show here that 5-Azacytidine treatment leads to increased T-cell recognition of tumor cells. T-cell responses against a large panel of cancer-testis antigens were detected before treatment, and these responses were further induced upon initiation of treatment. These characteristics point to an ideal combination of 5-Azacytidine and immune therapy to preferentially boost T-cell responses against cancer-testis antigens. To initiate such combination therapy, essential knowledge is required about the general immune modulatory effect of 5-Azacytidine. We therefore examined potential treatment effects on both immune stimulatory (CD8 and CD4 T cells and Natural ...
Gastric cancers are responsible for the second most cancer-related deaths worldwide. Although medical and surgical treatments have improved for gastric cancers, survival rates remain poor for both lung and gastric cancer patients.. Currently, approaches for immunotherapy in gastric cancer rely on the use of immunocytes, white blood cells that produce antibodies or trigger an immune response. Specifically, the current immunotherapy is designed to activate tumor specific cytotoxic T cells or to specifically bind target molecules or proteins expressed on the malignant tumor cells. In their research, a number of tumor rejection antigens have also been identified.. Experimental vaccination strategies are also in trial, including use of whole protein and peptide vaccines based on identification of peptides recognized by cytotoxic T lymphocytes and helper T lymphocytes. Tumor rejection antigens are selectively expressed in human tumors including gastric cancer, which can be recognized by cytotoxic T ...
Vaccines that prevent disease have profoundly changed the lives of billions of people around the world," says Matthew M. Davis, M.D., MAPP, associate professor of pediatrics and internal medicine at the University of Michigan Medical School. "A national strategy for therapeutic cancer vaccines would help emphasize development and regulatory approval for vaccines targeting cancers that currently do not have other good therapeutic options ...
Much has been learned in recent years concerning the nature of tumor antigens recognized by T cells. To apply this knowledge clinically, the nature of the host response to individual and multiple tumor antigens has to be characterized. This will help to define the efficacy of immune surveillance and the immune status of the host following exposure to tumor antigens expressed on pre-neoplastic tissue. To approach these questions, we have developed a transgenic mouse which expresses the tumor-specific antigen P91A. The single amino acid substitution in P91A results in the expression of a new MHC class I (H-2Ld)-binding peptide. In transgenic tissue, the H-2Ld/P91A complex is expressed in isolation from other tumor-associated antigens, allowing definition of the immune response to a single defined tumor antigen, a situation closely analogous to events during tumorigenesis. We show that CD8+ T cell immune surveillance of P91A is ineffective without the introduction of a helper determinant operating ...
Multiple intravenous injections of a cDNA library, derived from human melanoma cell lines and expressed using the highly immunogenic vector vesicular stomatitis virus (VSV), cured mice with established melanoma tumors. Successful tumor eradication was associated with the ability of mouse lymphoid cells to mount a tumor-specific CD4 + interleukin (IL)-17 recall response in vitro. We used this characteristic IL-17 response to screen the VSV-cDNA library and identified three different VSV-cDNA virus clones that, when used in combination but not alone, achieved the same efficacy against tumors as the complete parental virus library. VSV-expressed cDNA libraries can therefore be used to identify tumor rejection antigens that can cooperate to induce anti-tumor responses. This technology should be applicable to antigen discovery for other cancers, as well as for other diseases in which immune reactivity against more than one target antigen contributes to disease pathology. © 2012 Nature America, Inc. ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
My research has focused on the discovery and clinical development of novel cancer immunotherapeutics targeting the self/tumor antigen guanylyl cyclase C (GUCY2C; GCC). Current research projects focus on:. 1. Cancer Mucosa Antigens as Immunotherapeutic Targets for Metastatic Tumors. Immunotherapy for human cancers is hindered, in part, by a lack of suitable target antigens. This is particularly relevant in tumors derived from mucosal tissues such as colorectal cancer, in which antigens that are sufficiently immunogenic, tumor-restricted and shared among patients are lacking, and for which conventional therapeutics are poorly efficacious. We have explored a novel class of tumor-associated antigens fulfilling these criteria by exploiting immune compartmentalization, which restricts cross-talk between systemic and mucosal immune compartments. This compartmentalization limits systemic tolerance to mucosa-restricted self-antigens and shields mucosa from systemic autoimmune responses. Thus, a novel ...
Antibody Panel to Epithelial Cell Surface Antigen EpCAMAcris Antibodies offers a full range of thoroughly evaluated antibodies for specific detection…
NY-ESO-1 and LAGE-1 are cancer testis antigens with an ideal profile for tumor immunotherapy, combining up-regulation in many cancer types with highly restricted expression in normal tissues and sharing a common HLA-A*0201 epitope, 157-165. Here, we present data to describe the specificity and anti-tumor activity of a bifunctional ImmTAC, comprising a soluble, high-affinity T-cell receptor (TCR) specific for NY-ESO-1157-165 fused to an anti-CD3 scFv. This reagent, ImmTAC-NYE, is shown to kill HLA-A2, antigen-positive tumor cell lines, and freshly isolated HLA-A2- and LAGE-1-positive NSCLC cells. Employing time-domain optical imaging, we demonstrate in vivo targeting of fluorescently labelled high-affinity NYESO-specific TCRs to HLA-A2-, NYESO- 1157-165-positive tumors in xenografted mice. In vivo ImmTAC-NYE efficacy was tested in a tumor model in which human lymphocytes were stably co-engrafted into NSG mice harboring tumor xenografts; efficacy was observed in both tumor prevention and ...
Sigma-Aldrich offers abstracts and full-text articles by [Achim A Jungbluth, Scott Ely, Maurizio DiLiberto, Ruben Niesvizky, Barbara Williamson, Denise Frosina, Yao-Tseng Chen, Nina Bhardwaj, Selina Chen-Kiang, Lloyd J Old, Hearn Jay Cho].
The worlds first wiki where authorship really matters. Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts.
The worlds first wiki where authorship really matters. Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts.
Time: 12:30-1:30 p.m.. Abstract: Through flow cytometry analysis, cell sorting and in vitro techniques, AgonOx has developed a workflow for detecting, isolating and expanding endogenous tumor antigen-specific CD8 T cells from individuals own tumor tissue (Duhen, et al, Nature Communications, volume 9, Article number: 2724 (2018)). The highly enriched tumor-reactive T cells are grown in vitro with a method optimized to achieve large cellular expansion and to maintain a broad repertoire of tumor-reactive T cell clones. The expanded T cell product typically retains much of its original T cell clonal diversity and preserves or reinvigorates its tumor-lytic potential. This platform yields a uniquely personalized subject-derived product for individuals from a wide variety of tumor types. This tumor-specific T cell product is specific/personalized for each subject and has clinical research applications in the immune oncology field. ...
The idea that tumors could be recognized and rejected by the immune system was initially proposed in the late 19th century upon the observation that rare spontaneous tumor regressions occurred following infections, which may result in general activation of the immune system.1. More recently, preclinical studies revealed that tumors express immunogenic antigens and that these antigens induce immune responses that are able to protect against subsequent tumor challenges.2 Patients with melanoma were demonstrated to have T cells with specific activity against melanoma cells, and these cells were shown to be able to cause cancer regression when stimulated outside the body and returned to the patient.3-5. Over the last few years it has been recognized that the immune system in many patients has the ability to respond to cancer, but is usually prevented from doing so by immune defenses present in cancer cells. Many researchers and companies are studying a variety of means to overcome these defenses and ...
Definition : Immunoassay reagents intended to perform qualitative and/or quantitative analyses on a body fluid sample (e.g., serum) to determine the oncofetal antigen soft keratin (i.e., cytokeratin) fragment 19, referred to as CYFRA 21-1, typically found in the serum of patients with malignant tumors. The detection of the tumor marker CYFRA 21-1 (cytokeratin 19) is used in monitoring of non-small cell lung cancer and squamous cell carcinomas; its presence in pleural effusion is considered an aid for discriminating benign from malignant diseases.. Entry Terms : "Cytokeratin 19 Fragments Determination Reagents" , "CYFRA 21-1 Determination Reagents" , "Reagents, Immunoassay, Tumor Marker, Oncofetal, CYFRA 21-1". UMDC code : 19839 ...
Paschen, A.*, Song, M.*, Osen, W*., Nguyen, X. D., Mueller-Berghaus, J., Fink, D., Daniel, N., Donzeau, M., Nagel, W., Kropshofer, H. and Schadendorf, D.,Detection of spontaneous CD4+ T-cell responses in melanoma patients against a tyrosinase-related protein-2-derived epitope identified in HLA-DRB1*0301 transgenic mice. Clin Cancer Res 2005. 11: 5241-5247. Osen, W., Soltek, S.*, Song, M.*, Leuchs, B., Steitz, J., Tuting, T., Eichm ller, S. B., Nguyen, X. D., Schadendorf, D. and Paschen, A., Screening of human tumor antigens for CD4 T cell epitopes by combination of HLA-transgenic mice, recombinant adenovirus and antigen peptide libraries. PLoS One 2010. 5: e14137.. Gardyan, A.*, Osen, W.*, Zornig, I., Podola, L., Agarwal, M., Aulmann, S., Ruggiero, E., Schmidt, M., Halama, N., Leuchs, B., von Kalle, C., Beckhove, P., Schneeweiss, A., Jager, D. and Eichm ller, S. B., Identification of NY-BR-1-specific CD4(+) T cell epitopes using HLA-transgenic mice. Int J Cancer 2015. 136: 2588-2597.. Hao, S., ...
Approximately 40% of human melanomas express a tumor specific antigen referred to as melanoma antigen-1 (MAGE-1). Molecular analysis has revealed that the gene encoding MAGE-1 is present in normal cells as well as in tumor cells, and there is no evidence that it is mutated in cancer cells. However, as has been seen in some animal tumors, the gene is silent in normal adult cells; whether or not it is expressed during development remains to be determined. CD8+ cytotoxic T cells specific for MAGE-1 can be obtained by culturing tumor cells with patients lymphocytes in vitro. ...
ERYtech is developing immunotherapies using red blood cells (RBCs) as a natural delivery system of tumour-associated antigen to antigen presenting cells (APCs),
DI-fusion, le Dépôt institutionnel numérique de lULB, est loutil de référencementde la production scientifique de lULB.Linterface de recherche DI-fusion permet de consulter les publications des chercheurs de lULB et les thèses qui y ont été défendues.
We have demonstrated that after injection of CCL3 and CCL20, F4/80-B220-CD11c+ DC precursors are quickly recruited into the peripheral blood. Furthermore, these CCL3 and CCL20-recruited DCs, when modified with tumor antigen gene MAGE-1, could induce not only an effective CTL response against gastric cancer cells ex vivo but also therapeutic, anti-tumor immunity in both subcutaneous tumor and pulmonary metastatic tumor models.. Among many different immunotherapeutic strategies currently being evaluated, DC-based vaccination has attracted particular attention as a proven safe and potent therapy against tumors [14, 16]. Induction of tumor immunity can be initiated by effectors of innate immunity and can be further developed by cells of adaptive immunity, with DCs playing a central regulatory role. Several steps are involved including (a) recognition of tumor molecules by DC precursors, (b) direct and IFN-γ-mediated killing of transformed cells by NK/NK T cells activated by DCs, (c) capture and ...
Rat monoclonal EpCAM antibody [G8.8] validated for WB, IP, IHC and tested in Mouse. Referenced in 2 publications and 1 independent review. Immunogen…
The analysis of spontaneous and vaccine-induced immune responses against cancer has led to the identification of a large number of tumor antigens that are classified according to their expression pattern, function or origin into five different categories: cancer-testis (CT) antigens (i.e. MAGE, BAGE, NY-ESO-1); differentiation antigens (i.e. Melan A/MART-1, tyrosinase, CEA, NY-BR-1); mutational antigens (i.e. MUM-1, p53, CDK-4); overexpressed self antigens (i.e. HER-2/neu, p53); viral antigens (i.e. HPV, HCV). Since antigen-specific CD8+ T-cell responses were first identified to be associated with tumor regression in single patients, multiple approaches have been initiated to develop specific and non-specific cancer vaccines.. Antigenic peptides derived from MAGE, Melan A/MART-1, tyrosinase, and gp100, that are recognized by CD8+ T lymphocytes in the context of defined MHC class I molecules, have been used first to immunize patients with advanced melanoma. Objectives of the first clinical ...
The first human (mammalian) members of the MAGE (Melanoma-associated antigen) gene family that have been described are expressed in tumor cells but silent in
The front line The front line of your immune system does its best to stop foreign invaders from getting into your body in the first place. However if a virus, bacteria, or parasite still makes its way through, the rest of your immune system will get to work.. The "army" of our immune system is made up of different types of white blood cells, all called defender cells. We make about a billion of these defender cells in our bone marrow every day.. What do the white blood cells do?. Some of these white blood cells - called macrophages - circulate around our body looking for germs and infection. As soon as they see something they dont recognise, they attack. Your macrophages can tell the difference between your own cells and invading cells because of antigens. Antigens are like ID-tags on the surface of every cell. If a new cell doesnt carry your unique antigen, then your immune system knows its foreign and sees it as a threat.. Did you know that macrophage literally means "big eater", which is ...
3. Producing antibodies - each pathogen has unique antigens (surface molecules) when WBC come across a foreign antigen it will start to produce proteins called antibodies. Antibodies lock onto the invading cell and kill them. These are then produced rapidly and some remain as memory cells. Memory cells are remember the antigen and kill it if the body ever becomes infected again. This person is then naturally immune.. ...
The latest market report published by Credence Research, Inc. "Global Carcinoembryonic Antigen (CEA) Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 - 2023," the carcinoembryonic antigen (CEA) market was valued at USD 1,624.2 Mn in 2015, and is expected to reach USD 2,787.3 Mn by 2023, expanding at a CAGR of 6.4% from 2016 to 2023.. Market Insights. According to Quest Diagnostics, CEA is an oncofetal glycoprotein present in the gastrointestinal tract and body fluids of the embryo and fetus. This antigen is also present in certain adult gastrointestinal cells, including the mucosal cells of the colorectum, and small amounts are present in blood. Market experts suggest that key growth drivers assisting the growth of CEA market comprises high prevalence of cancer, mounting global geriatric population base, high demand for minimally invasive diagnostic procedures in cancer and increasing application of CEA for diagnosis at several stages of cancer. In addition, a few ...
TAG72, 0.1 mg. Tumor-associated glycoprotein (TAG) 72 is a tumor marker, identified and characterized using two different monoclonal antibodies B72.3 and CC49.
... Carcinoembryonic antigen (CEA) is a glycoprotein involved in cell adhesion. It is normally produced during fetal development, but the production of CEA stops before birth.
A therapeutic cancer vaccine from Oxford BioMedica that failed in a clinical study may still help a subset of patients, researchers said on Tuesday.
Free Online Library: France - CARCINOEMBRYONIC ANTIGEN. by Mena Report; Business, international Carcinoembryonic antigen CEA (Oncology)
Gene Information This gene is a member of the GAGE family which is expressed in a variety of tumors and in some fetal and reproductive tissues. The protein encoded by this gene shares a sequence similarity with other GAGE/PAGE proteins. It may also belong to a family of CT (cancer-testis) antigens. Multiple alternatively spliced transcript variants encoding distinct isoforms have been found for this gene but the biological validity of some variants have not been determined. [provided by RefSeq Jul 2008]. ...
The Lens serves almost all the patents and scholarly work in the world as a free, open and secure digital public good, with user privacy a paramount focus.
The purpose of this study is to find out which doses of the study drug are safe to give to patients with gastrointestinal (colon, liver, pancreas, stomach) solid tumors. The study drug is RO6958688. RO6958688 is an antibody that targets CEA on the tumor cells and may activate the immune system in targeting cancer cells. The study will also explore how the study drug works in the body and on the tumor. The study also wants to find out if RO6958688 can slow down the growth of tumors or stop the cancer.
ラット・モノクローナル抗体 ab92382 交差種: Ms 適用: WB,IP,IHC-Fr…EpCAM抗体一覧…画像、プロトコール、文献などWeb上の情報が満載のアブカムの Antibody 製品。国内在庫と品質保証制度も充実。
This test measures a protein called carcinoembryonic antigen (CEA) in your blood. This protein is present on some types of cancer cells.
This test measures a protein called carcinoembryonic antigen (CEA) in your blood. This protein is present on some types of cancer cells.
This test measures a protein called carcinoembryonic antigen (CEA) in your blood. This protein is present on some types of cancer cells.
Mouse Monoclonal Anti-TAG-72 Antibody (B72.3 + CA72/733) [DyLight 405]. Validated: WB, Flow, ICC/IF, IHC-Fr, IHC-P. Tested Reactivity: Human, Rat, Bovine, and more. 100% Guaranteed.
Mouse Monoclonal Anti-TAG-72 Antibody (B72.3 + CC49) [PE]. Validated: Flow. Tested Reactivity: Human, Rat, Bovine, and more. 100% Guaranteed.
Gentaur molecular products has all kinds of products like :search , ARP \ Antigens P4HB, 18-508aa, Human, His tag, E.coli, Recombinant \ 01-1910 for more molecular products just contact us
Tumor-associated antigens such as NY-ESO-1 are expressed in a variety of solid tumors but absent in mature healthy tissues with the exception of germline cells. expanded with IL-2 IL-7 and IL-15. Large numbers of NY-ESO-1-specific CD4+ T cells with a TH1 cytokine profile and lower numbers of cytokine-secreting CD8+ T cells could be generated from […]. ...
The antigens found on the red blood cell (A, B, and Rh). These antigens determine the type (A, B, AB, or if not present at all O) and whether it is positive or negative (Rh factor). ...
Looking for online definition of Renal carcinoma antigen NY-REN-62 in the Medical Dictionary? Renal carcinoma antigen NY-REN-62 explanation free. What is Renal carcinoma antigen NY-REN-62? Meaning of Renal carcinoma antigen NY-REN-62 medical term. What does Renal carcinoma antigen NY-REN-62 mean?
Previous reports have described antigens that are recognized on human melanoma cells by autologous cytolytic T lymphocytes (CTL). The genes coding for a number of these antigens have been identified. Here we report the cloning of a gene that codes for an antigen recognized by autologous CTL on a human renal carcinoma cell line. This antigen is presented by HLA-B7 and is encoded by a new gene that we have named RAGE1. No expression of RAGE1 was found in normal tissues other than retina. RAGE1 expression was found in only one of 57 renal cell carcinoma samples, and also in some sarcomas, infiltrating bladder carcinomas, and melanomas. This represents the first identification of an antigen recognized by autologous CTL on a renal tumor. ...
Aims: Pancreatic adenocarcinoma is an aggressive gastrointestinal malignancy with only a few long-term survivors even after radical surgery. Patients with ampullary cancer have a better prognosis but adjuvant therapy needs further improvement. Epithelial cell adhesion molecule (Ep-CAM) is strongly expressed in a variety of epithelial cancers and represents a promising target for immunological tumour therapy. Thus, the aim of this study was to investigate Ep-CAM expression and its potential prognostic impact in pancreatic and ampullary carcinomas.. Methods: Ep-CAM expression was investigated retrospectively by immunohistochemistry in paraffin-embedded primary tumour tissue samples from a series of consecutive patients with pancreatic (n = 153) and ampullary cancer (n = 34).. Results: Ep-CAM overexpression was observed in 85 of 153 pancreatic cancer specimens (56%) and in 29 of 34 ampullary cancer samples (85%). Overall, Ep-CAM failed to be an independent prognostic marker. However, subgroup ...
TY - JOUR. T1 - Attachment-oriented endoscopic surgical management for inverted papillomas in the nasal cavity and paranasal sinuses. AU - Makihara, Seiichiro. AU - Kariya, Shin. AU - Naito, Tomoyuki. AU - Uraguchi, Kensuke. AU - Matsumoto, Junya. AU - Noda, Yohei. AU - Okano, Mitsuhiro. AU - Nishizaki, Kazunori. PY - 2019/1/1. Y1 - 2019/1/1. N2 - Objective: The treatment of all forms of sinonasal inverted papilloma (IP) is a complete, wide, local resection. The main surgical purpose is to remove all diseased mucosa and mucoperiosteum, together with a cuff of normal-looking mucosa at the attachment site, followed by drilling and/or coagulation. Our aim is to present our experiences in endoscopic surgical management of IP by using attachment-oriented excision. Methods: We present 20 cases of sinonasal IP. The data collected includes the histopathological diagnosis, staging, extension of the tumor, tumor attachment site, approach to surgery, serum squamous cell carcinoma antigen (SCCA) level, and ...
TY - JOUR. T1 - Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase. AU - Vonderheide, R. H.. AU - Anderson, Karen. AU - Hahn, W. C.. AU - Butler, M. O.. AU - Schultze, J. L.. AU - Nadler, L. M.. PY - 2001. Y1 - 2001. N2 - Purpose: We have reported previously that the telomerase catalytic subunit, human telomerase reverse transcriptase (hTERT), is a widely expressed tumor-associated antigen recognized by CTLs. A nine-amino acid peptide derived from hTERT binds strongly to HLA-A2 antigen and elicits CTL responses against a broad panel of hTERT+ tumors (but not hTERT+ hematopoietic progenitor cells). The applicability of hTERT as a potential target for anticancer immunotherapy would be widened by the identification of epitopes restricted to other common HLA alleles, such as HLA-A3 antigen. Experimental Design: Using a method of epitope deduction, HLA-A3-restricted peptide epitopes were screened from hTERT and tested for ...
TY - JOUR. T1 - Extracellular matrix metalloproteinase inducer (CD147) confers resistance of breast cancer cells to anoikis through inhibition of bim. AU - Yang, Jin Ming. AU - ONeill, Peter. AU - Jin, Wei. AU - Foty, Ramsey. AU - Medina, Daniel J.. AU - Xu, Zude. AU - Lomas, Mehnaaz. AU - Arndt, Greg M.. AU - Tang, Yi. AU - Nakada, Marian. AU - Yan, Li. AU - Hait, William N.. PY - 2006/4/7. Y1 - 2006/4/7. N2 - Overexpression of extracellular matrix metalloproteinase inducer (EMMPRIN or CD147), a member of the immunoglobulin family and a glycoprotein enriched on the surface of tumor cells, promotes invasion, metastasis, and growth and survival of malignant cells and confers resistance to some chemotherapeutic drugs. However, the molecular mechanisms underlying the actions of EMMPRIN are not fully understood. In this study we sought to determine whether EMMPRIN contributes to the malignant phenotype of breast cancer by inhibiting anoikis, a form of apoptosis induced by loss or alteration of ...
The incidence of thyroid cancer, the most common endocrine malignancy, continues to increase steadily during the past few decades worldwide [1, 2]. The majority of thyroid cancer types are classified as: follicular epithelial cell-derived papillary thyroid cancer (PTC), follicular thyroid cancer (FTC), anaplastic thyroid cancer (ATC), and para-follicular C-cell derived medullary thyroid cancer (MTC) [3]. The prognosis of patients with thyroid cancer is closely correlated with local invasion outside the thyroid capsule and the development of distant metastases [4]. Therefore, dissecting the molecular mechanisms underlying thyroid cancer invasion and metastasis is still imperative and may put new insight into the clinical treatment of thyroid cancer.. Human tumor-associated calcium signal transducer 2 (TACSTD2), also known as trophoblast cell-surface antigen 2 (Trop2), is a type I transmembrane glycoprotein originally identified in human placental trophoblastic tissue [5]. As a cell surface ...
Background: Squamous cell carcinoma accounts for 1% of primary thyroid malignancies and is characterized by a rapidly unfavorable outcome. Case presentation: A 64-year-old woman presented with a painless mass in the left neck, coexisting with thyroid goiter. Total thyroidectomy with lymphadenectomy was performed and a primary thyroid squamous cell cancer was confirmed histologically after excluding any other possible primary malignancies. The tumors immunohistochemical profile was explored using a large panel of antibodies. The tumor featured a positive immunoreaction to cytokeratins 7-19 and to squamous cell carcinoma antigen. Low-molecular-weight cytokeratins 5- 6 and epithelial membrane antigen were also expressed. The neoplasms proliferative index (Mib1) was 60%. No immunostaining was detected for cytokeratins 10-20, thyroglobulin, TTF-1, CD5, galectin-3 or p53. Conclusions: This case of primary thyroid squamous cell carcinoma immunohistochemically profiled using a large panel of ...

CHAPTER 104 PLASMA CELL NEOPLASMS: GENERAL CONSIDERATIONS | Free Medical TextbookCHAPTER 104 PLASMA CELL NEOPLASMS: GENERAL CONSIDERATIONS | Free Medical Textbook

BAIRD Definition and History Plasma Cell Neoplasms Essential Monoclonal Gammopathy Chronic Cold Agglutinin Syndrome ... GENERAL CONSIDERATIONS Williams Hematology CHAPTER 104 PLASMA CELL NEOPLASMS: GENERAL CONSIDERATIONS STEPHEN M. ... Malignant B cells may express both early and late B-cell antigens along with antigens characteristic of granulocytes, monocytes ... PLASMA CELL NEOPLASMS. Plasma cell neoplasms are monoclonal tumors comprised of plasma cells and their precursors. All the ...
more infohttps://medtextfree.wordpress.com/2012/01/23/chapter-104-plasma-cell-neoplasms-general-considerations/

WHO HQ Library catalog ›

    Results of search for su:{Antigens, Neoplasm}WHO HQ Library catalog › Results of search for 'su:{Antigens, Neoplasm}'

Fetal antigens and cancer. Material type: Book; Format: print Publisher: London : Pitman, 1983Availability: Items available for ...
more infohttps://kohahq.searo.who.int/cgi-bin/koha/opac-search.pl?q=su:%7BAntigens,%20Neoplasm%7D

Carcinoembryonic Antigen Present in Human Colonic Neoplasms Serially Propagated in Hamsters | ScienceCarcinoembryonic Antigen Present in Human Colonic Neoplasms Serially Propagated in Hamsters | Science

Carcinoembryonic Antigen Present in Human Colonic Neoplasms Serially Propagated in Hamsters. By David M. Goldenberg, Hans J. ... Carcinoembryonic Antigen Present in Human Colonic Neoplasms Serially Propagated in Hamsters. By David M. Goldenberg, Hans J. ... Carcinoembryonic Antigen Present in Human Colonic Neoplasms Serially Propagated in Hamsters Message Subject. (Your Name) has ... Carcinoembryonic antigen, as measured by radioimmunoassay, is present in two different human colonic tumors that have been ...
more infohttp://science.sciencemag.org/content/175/4026/1117

Tumour-associated transplantation antigens of neoplasms induced by a n by D B. Jones and M Moore"Tumour-associated transplantation antigens of neoplasms induced by a n" by D B. Jones and M Moore

Tumour-associated transplantation antigens of neoplasms induced by a naturally occurring murine sarcoma virus (fbj-msv). ... Neoplasm:, Serology: Antigen, Transplantation:, Types of Tumors:, Rickettsia, Virus:, Strains: CBA, CBA/H-T6T6 ... Jones, D B. and Moore, M, "Tumour-associated transplantation antigens of neoplasms induced by a naturally occurring murine ...
more infohttps://mouseion.jax.org/ssbb1973/1898/

Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells...Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells...

Antigens, Neoplasm. Grant support. *R01 CA134622-01A1/CA/NCI NIH HHS/United States ... The nature and site of tumor-antigen presentation to immune T cells by bone-marrow-derived cells within the tumor ... Marginating Dendritic Cells of the Tumor Microenvironment Cross-present Tumor Antigens and Stably Engage Tumor-Specific T cells ... Marginating Dendritic Cells of the Tumor Microenvironment Cross-present Tumor Antigens and Stably Engage Tumor-Specific T cells ...
more infohttps://www.ncbi.nlm.nih.gov/pubmed/22439936?dopt=Abstract

Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells.  - PubMed - NCBITumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells. - PubMed - NCBI

Antigens, Neoplasm. Grant support. *R01 CA084488/CA/NCI NIH HHS/United States ... C. Antigen specific IL-2 production. LN cells isolated from mice as described above were cultured in the presence of specific ... D. Antigen-specific proliferation. LN cells isolated from mice as described above were cultured for 4 days in triplicates in U- ... LN cells were isolated on day 10 after immunization and percentage of antigen-specific CD8+Valpha2+ T cells was determined by ...
more infohttps://www.ncbi.nlm.nih.gov/pubmed/16177103

The reversed apical pattern of MUC1 expression is characteristics of invasive micropapillary carcinoma of the breast.The reversed apical pattern of MUC1 expression is characteristics of invasive micropapillary carcinoma of the breast.

Antigens, Neoplasm. Breast Neoplasms / metabolism*, pathology. Carcinoma, Ductal, Breast / metabolism*, secondary. Carcinoma, ... 0/Antigens, Neoplasm; 0/MUC1 protein, human; 0/Mucin-1; 0/Mucins ...
more infohttp://www.biomedsearch.com/nih/reversed-apical-pattern-MUC1-expression/16518063.html

Assessment of angiogenesis by CD105 antigen in epithelial salivary gland neoplasms with diverse metastatic behavior | BMC...Assessment of angiogenesis by CD105 antigen in epithelial salivary gland neoplasms with diverse metastatic behavior | BMC...

Assessment of angiogenesis by CD105 antigen in epithelial salivary gland neoplasms with diverse metastatic behavior. ... Antigen retrieval was performed in deparaffinized, rehydrated samples with 1 mM EDTA (pH 8.0) in microwave environment (3 × 5 ... It was initially gathered cases of epithelial salivary gland neoplasms that were surgically resected as the first therapeutic ... Among malignant neoplasms, there was graded frequency of positivity for CD105, with MEC being the highest (85.0%), followed by ...
more infohttps://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-9-391

MEDLINE - Resultado p gina 1
	MEDLINE - Resultado p gina 1

0 (Antigens, Bacterial); 0 (Antigens, Neoplasm); 0 (Antigens, Viral); 0 (Biomarkers, Tumor); 0 (CTLA-4 Antigen); 0 (Epitopes, T ... 0 (Antigens, Bacterial); 0 (Drug Carriers); 0 (Escherichia coli Proteins); 0 (K88 antigen, E coli); 0 (Plant Lectins); 0 ( ... In the current study, we assessed serum IgA binding to the B. burgdorferi peptide antigens, C6, the target of the FDA-cleared ... After the second immunization, the antigen-specific CD4 cell responses for IFN-γ, IL-2, IL-4 and IL-10 were monitored by ...
more infohttp://bases.bireme.br/cgi-bin/wxislind.exe/iah/online/?IsisScript=iah/iah.xis&nextAction=lnk&base=MEDLINE&lang=p&format=detailed.pft&indexSearch=EX&exprSearch=D23.050.161

Expression of common acute lymphoblastic leukaemia antigen and terminal deoxynucleotidyl transferase in normal mononuclear...Expression of common acute lymphoblastic leukaemia antigen and terminal deoxynucleotidyl transferase in normal mononuclear...

A high percentage of cALL antigen positive cells and later on TdT containing cells appeared during culture. The cALL+ cells ... Antigens, Neoplasm / analysis*. Cell Differentiation. Cells, Cultured. DNA Nucleotidylexotransferase / analysis*. DNA ... 0/Antigens, Neoplasm; EC 2.7.7.-/DNA Nucleotidyltransferases; EC 2.7.7.31/DNA Nucleotidylexotransferase ... A high percentage of cALL antigen positive cells and later on TdT containing cells appeared during culture. The cALL+ cells ...
more infohttp://www.biomedsearch.com/nih/Expression-common-acute-lymphoblastic-leukaemia/7038845.html

MEDLINE - Resultado p gina 1
	MEDLINE - Resultado p gina 1

0 (Antigens, Neoplasm); 0 (Cancer Vaccines); 0 (HLA Antigens). [Em] M s de entrada:. 1705. ... However, human leucocyte antigen (HLA) class II types presumably associated with acquired TTP were not identified in the ... We applied H-2Db- and H-2Kb-specific neoantigen prediction algorithms to identify candidate tumor antigens. To validate the ... The "cancer immunogenomics" approach has facilitated the search for tumor-specific antigens over the past 4 years by applying ...
more infohttp://bases.bireme.br/cgi-bin/wxislind.exe/iah/online/?IsisScript=iah/iah.xis&nextAction=lnk&base=MEDLINE&lang=p&format=detailed.pft&indexSearch=EX&exprSearch=H01.158.273.343.420

Cytosolic levels of neuron-specific enolase in squamous cell carcinomas of the lung. | CureHunterCytosolic levels of neuron-specific enolase in squamous cell carcinomas of the lung. | CureHunter

Antigens, CD44 (biosynthesis) *Antigens, Neoplasm (biosynthesis) *Biomarkers, Tumor. *CA-125 Antigen (biosynthesis) ...
more infohttp://www.curehunter.com/public/pubmed14535589.do

adenocarcinoma antigen recognized by T cells-1
     Summary Report | CureHunteradenocarcinoma antigen recognized by T cells-1 Summary Report | CureHunter

... a 60 kDa tumor-rejection antigen recognized by cytotoxic T lymphocytes infiltrating into a lung adenocarcinoma; amino acid ... Antigens: 114404*Neoplasm Antigens: 2058*adenocarcinoma antigen recognized by T cells-1 ... adenocarcinoma antigen recognized by T cells-1. Subscribe to New Research on adenocarcinoma antigen recognized by T cells-1 ... a 60 kDa tumor-rejection antigen recognized by cytotoxic T lymphocytes infiltrating into a lung adenocarcinoma; amino acid ...
more infohttp://www.curehunter.com/public/keywordSummaryC413657-adenocarcinoma-antigen-recognized-by-T-cells-1.do

Heat map profile of miRNA expression in the DU145-LN ce | Open-iHeat map profile of miRNA expression in the DU145-LN ce | Open-i

Antigens, Neoplasm/metabolism. *Cadherins/metabolism. *Cell Adhesion. *Cell Adhesion Molecules/metabolism. *Cell Line, Tumor ...
more infohttps://openi.nlm.nih.gov/detailedresult.php?img=PMC3818652_srep03151-f4&req=4

SDS-PAGE and Western blot analysis of purified SC142  | Open-iSDS-PAGE and Western blot analysis of purified SC142 | Open-i

SC142-reactive antigen are highly glycosylated glycoproteins expressed on tissues of gastric and colon cancers but not on ... SC142-reactive antigen are highly glycosylated glycoproteins expressed on tissues of gastric and colon cancers but not on ... Murine SC142 antibody specific for the SC142-reactive antigen has been produced by immunisation with SNU16 stomach cancer cells ... Murine SC142 antibody specific for the SC142-reactive antigen has been produced by immunisation with SNU16 stomach cancer cells ...
more infohttps://openi.nlm.nih.gov/detailedresult.php?img=PMC2376138_87-6600365f3&req=4

Bioflavonoids as Poisons of Human Topoisomerase II Alpha and II Beta - PubMedBioflavonoids as Poisons of Human Topoisomerase II Alpha and II Beta - PubMed

Antigens, Neoplasm / chemistry Actions. * Search in PubMed * Search in MeSH * Add to Search ...
more infohttps://pubmed.ncbi.nlm.nih.gov/17458941/

Techniques for studies on growth characteristics of human prostatic cancer cells  - Publikationsserver der Universität...Techniques for studies on growth characteristics of human prostatic cancer cells - Publikationsserver der Universität...

Antigens, Neoplasm. MESH. Biotechnology. MESH. Cell Division. MESH. Cell Separation. MESH. DNA, Neoplasm/metabolism. MESH. ...
more infohttps://epub.uni-regensburg.de/15256/

The treatment of patients with disseminated malignant melanoma by vaccination with autologous cell hybrids of tumor cells and...The treatment of patients with disseminated malignant melanoma by vaccination with autologous cell hybrids of tumor cells and...

Antigens, Neoplasm. MESH. Autoantigens. MESH. Cancer Vaccines/therapeutic use. MESH. Dendritic Cells/immunology. MESH. ... Clinical trials using dendritic cells (DC) loaded with peptides corresponding to tumor antigens are ongoing in several ... Clinical trials using dendritic cells (DC) loaded with peptides corresponding to tumor antigens are ongoing in several ... and this strategy is not appropriate for patients with rare HLA types or with tumors without defined antigens. A clinical pilot ...
more infohttps://epub.uni-regensburg.de/14365/

Antigens, CD146 | Profiles RNSAntigens, CD146 | Profiles RNS

Antigens [D23.050]. *Antigens, Neoplasm [D23.050.285]. *Melanoma-Specific Antigens [D23.050.285.439]. *Antigens, CD146 [D23.050 ... "Antigens, CD146" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH (Medical Subject ... This graph shows the total number of publications written about "Antigens, CD146" by people in this website by year, and ... Below are the most recent publications written about "Antigens, CD146" by people in Profiles. ...
more infohttps://profiles.umassmed.edu/display/117333

epithelioid leiomyosarcoma diagnosis drug therapy 2000:2010[pubdate] *count=100 - BioMedLib™ search engineepithelioid leiomyosarcoma diagnosis drug therapy 2000:2010[pubdate] *count=100 - BioMedLib™ search engine

Liver Neoplasms / secondary. Neoplasm Proteins. Uterine Neoplasms / pathology. *[MeSH-minor] Actins / analysis. Adult. Antigens ... Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins ... Melanoma-Specific Antigens. Neoplasm Metastasis / pathology. Neoplasm Metastasis / therapy. *Genetic Alliance. consumer health ... Chemical-registry-number] 0 / Actins; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Melanoma-Specific Antigens; 0 / ...
more infohttp://www.bmlsearch.com/?kwr=epithelioid+leiomyosarcoma+diagnosis+drug+therapy+2000:2010%5Bpubdate%5D&cxts=100&stmp=b1

becker nevus 2005:2010[pubdate] *count=100 - BioMedLib™ search enginebecker nevus 2005:2010[pubdate] *count=100 - BioMedLib™ search engine

Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Melanins; 0 / Neoplasm ... Chemical-registry-number] 0 / Actins; 0 / Antigens, Neoplasm; 0 / Calmodulin-Binding Proteins; 0 / MART-1 Antigen; 0 / MLANA ... Neoplasms, Multiple Primary / diagnosis. Nevus, Pigmented / diagnosis. Skin Neoplasms / diagnosis. Soft Tissue Neoplasms / ... Neoplasm Proteins / analysis. Nevus / chemistry. Skin Neoplasms / chemistry. *MedlinePlus Health Information. consumer health ...
more infohttp://www.bmlsearch.com/?kwr=becker+nevus+2005:2010%5Bpubdate%5D&cxts=100&stmp=b0

Multiplexed Analysis of Glycan Variation on Native Proteins Captured by Antibody Microarrays - PubMedMultiplexed Analysis of Glycan Variation on Native Proteins Captured by Antibody Microarrays - PubMed

Antigens, Neoplasm / chemistry *. Actions. * Search in PubMed * Search in MeSH * Add to Search ... Prostate-specific Antigen Glycoprofiling as Diagnostic and Prognostic Biomarker of Prostate Cancer J Tkac et al. Interface ... The initial part of this review details the controversy behind the use of a serological level of prostate-specific antigen (PSA ...
more infohttps://pubmed.ncbi.nlm.nih.gov/17417647/

Accumulation of memory precursor cd8 t cells in regressing tumors following combination therapy with vaccine and anti-pd-1...Accumulation of memory precursor cd8 t cells in regressing tumors following combination therapy with vaccine and anti-pd-1...

... in regressing tumors and enhanced antigen reactivity of tumor-infiltrating CD8 T cells. It was also observed that blockade of ... in regressing tumors and enhanced antigen reactivity of tumor-infiltrating CD8 T cells. It was also observed that blockade of ... in regressing tumors and enhanced antigen reactivity of tumor-infiltrating CD8 T cells. It was also observed that blockade of ... in regressing tumors and enhanced antigen reactivity of tumor-infiltrating CD8 T cells. It was also observed that blockade of ...
more infohttps://mayoclinic.pure.elsevier.com/en/publications/accumulation-of-memory-precursor-cd8-t-cells-in-regressing-tumors

Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1<...Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1<...

Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1. ... Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1 ... Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1 ... T1 - Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen ...
more infohttps://jhu.pure.elsevier.com/en/publications/normal-tissue-depresses-while-tumor-tissue-enhances-human-t-cell--3

Development of a monoclonal antibody against a tumor-associated antigen<...Development of a monoclonal antibody against a tumor-associated antigen<...

Development of a monoclonal antibody against a tumor-associated antigen. W. W. Peng, Joseph Bressler, E. Tiffany-Castiglioni, J ... Development of a monoclonal antibody against a tumor-associated antigen. / Peng, W. W.; Bressler, Joseph; Tiffany-Castiglioni, ... The antigen also appears on tumor tissue of transformed oligodendrocytes but not on normal brain tissue. ... The antigen also appears on tumor tissue of transformed oligodendrocytes but not on normal brain tissue.", ...
more infohttps://jhu.pure.elsevier.com/en/publications/development-of-a-monoclonal-antibody-against-a-tumor-associated-a-6
  • Carcinoembryonic antigen, as measured by radioimmunoassay, is present in two different human colonic tumors that have been serially transplanted and maintained in the cheek pouches of unconditioned, adult golden hamsters. (sciencemag.org)
  • However, every single peptide-based vaccine can only be used in a patient with a given single HLA type, and this strategy is not appropriate for patients with rare HLA types or with tumors without defined antigens. (uni-regensburg.de)
  • This prolonged survival was associated with increase in number of Tc1 and Tc2 CD8 T cells with memory precursor phenotype, CD27IL- 7RhiT-betlo, and decrease in number of PD-1 dendritic cells (DC) in regressing tumors and enhanced antigen reactivity of tumor-infiltrating CD8 T cells. (elsevier.com)
  • We observed that using anti- PD-1 antibody and a multipeptide vaccine (consisting of immunogenic peptides derived from breast cancer antigens, neu, legumain, and b-catenin) as a combination therapy regimen for the treatment of breast cancer- bearing mice prolonged the vaccine-induced progression-free survival period. (elsevier.com)
  • This graph shows the total number of publications written about "Antigens, CD146" by people in this website by year, and whether "Antigens, CD146" was a major or minor topic of these publications. (umassmed.edu)
  • We describe how these genetic findings have enhanced insights into immunobiology, been clinically translated into CCR5 antagonists, allowed prioritization of antigens for vaccination efforts, and identified targets for genome-editing interventions. (bireme.br)
  • In general, immunotherapies can be considered either non-specific, such as a general immunomodulator (e.g., a cytokine), or tumor-specific (e.g., a vaccine that targets breast cancer tumor antigens). (elsevier.com)
  • It was initially gathered cases of epithelial salivary gland neoplasms that were surgically resected as the first therapeutic intervention in the period between 1998 and 2004. (biomedcentral.com)
  • A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. (wikipedia.org)
  • SC142-reactive antigen are highly glycosylated glycoproteins expressed on tissues of gastric and colon cancers but not on normal tissues. (nih.gov)
  • The antigen also appears on tumor tissue of transformed oligodendrocytes but not on normal brain tissue. (elsevier.com)